Search

Your search keyword '"Khanna, Nina"' showing total 929 results
Start Over Author "Khanna, Nina"
929 results on '"Khanna, Nina"'

105. Evaluation of the clinical relevance of the Biofire© FilmArray pneumonia panel among hospitalized patients

Author

Søgaard, Kirstine K., primary, Hinic, Vladimira, additional, Goldenberger, Daniel, additional, Gensch, Alexander, additional, Schweitzer, Michael, additional, Bättig, Veronika, additional, Siegemund, Martin, additional, Bassetti, Stefano, additional, Bingisser, Roland, additional, Tamm, Michael, additional, Battegay, Manuel, additional, Weisser, Maja, additional, Stolz, Daiana, additional, Khanna, Nina, additional, and Egli, Adrian, additional

Published
2023
Full Text
View/download PDF

106. Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study

Author

Hoenigl, Martin, primary, Salmanton-García, Jon, additional, Egger, Matthias, additional, Gangneux, Jean-Pierre, additional, Bicanic, Tihana, additional, Arikan-Akdagli, Sevtap, additional, Alastruey-Izquierdo, Ana, additional, Klimko, Nikolai, additional, Barac, Aleksandra, additional, Özenci, Volkan, additional, Meijer, Eelco F J, additional, Khanna, Nina, additional, Bassetti, Matteo, additional, Rautemaa-Richardson, Riina, additional, Lagrou, Katrien, additional, Adam, Kai-Manuel, additional, Akalin, Emin Halis, additional, Akova, Murat, additional, Arsic Arsenijevic, Valentina, additional, Aujayeb, Avinash, additional, Blennow, Ola, additional, Bretagne, Stéphane, additional, Danion, François, additional, Denis, Blandine, additional, de Jonge, Nick Alexander, additional, Desoubeaux, Guillaume, additional, Drgona, Lubos, additional, Erben, Nurettin, additional, Gori, Andrea, additional, García Rodríguez, Julio, additional, Garcia-Vidal, Carolina, additional, Giacobbe, Daniele Roberto, additional, Goodman, Anna L, additional, Hamal, Petr, additional, Hammarström, Helena, additional, Toscano, Cristina, additional, Lanternier, Fanny, additional, Lass-Flörl, Cornelia, additional, Lockhart, Deborah E A, additional, Longval, Thomas, additional, Loughlin, Laura, additional, Matos, Tadeja, additional, Mikulska, Malgorzata, additional, Narayanan, Manjusha, additional, Martín-Pérez, Sonia, additional, Prattes, Juergen, additional, Rogers, Benedict, additional, Rahimli, Laman, additional, Ruiz, Maite, additional, Roilides, Emmanuel, additional, Samarkos, Michael, additional, Scharmann, Ulrike, additional, Sili, Uluhan, additional, Sipahi, Oguz Resat, additional, Sivakova, Alena, additional, Steinmann, Joerg, additional, Trauth, Janina, additional, Turhan, Ozge, additional, Van Praet, Jens, additional, Vena, Antonio, additional, White, P Lewis, additional, Willinger, Birgit, additional, Tortorano, Anna Maria, additional, Arendrup, Maiken C, additional, Koehler, Philipp, additional, Cornely, Oliver A, additional, Tumbarello, Mario, additional, Talento, Alida Fe, additional, Ruiz, Alba C, additional, Racil, Zdenek, additional, Stoma, Igor, additional, Calbacho, Maria, additional, Van Wijngaerden, Eric, additional, Henriques, Júlia, additional, Jordan, Harriett, additional, Ferroni, Valentina, additional, Ozyurt, Ozlem Koyuncu, additional, Milacek, Christopher, additional, Krause, Robert, additional, Zurl, Christoph, additional, Backx, Matthijs, additional, Li, Ang, additional, Seufert, Raphael, additional, Tomazin, Rok, additional, Blankenheim, Yael, additional, Dávila-Valls, Julio, additional, García-Clemente, Paloma, additional, Freiberger, Tomas, additional, Buil, Jochem, additional, Meis, Jacques F, additional, Akyol, Deniz, additional, Guegan, Hélène, additional, and Logan, Clare, additional

Published
2023
Full Text
View/download PDF

110. Evaluation of the clinical relevance of the Biofire© FilmArray pneumonia panel among hospitalized patients.

Author

Søgaard, Kirstine K., Hinic, Vladimira, Goldenberger, Daniel, Gensch, Alexander, Schweitzer, Michael, Bättig, Veronika, Siegemund, Martin, Bassetti, Stefano, Bingisser, Roland, Tamm, Michael, Battegay, Manuel, Weisser, Maja, Stolz, Daiana, Khanna, Nina, and Egli, Adrian

Subjects
PNEUMONIA diagnosis, HOSPITAL patients, BRONCHOALVEOLAR lavage, MOLECULAR diagnosis, ACADEMIC medical centers, CONFIDENCE intervals, SCIENTIFIC observation, RESPIRATORY disease diagnosis, CULTURES (Biology), RETROSPECTIVE studies, RESEARCH funding, POLYMERASE chain reaction, SENSITIVITY & specificity (Statistics), LOGISTIC regression analysis, ODDS ratio
Abstract

Purpose: Panel PCR tests provide rapid pathogen identification. However, their diagnostic performance is unclear. We assessed the performance of the Biofire© FilmArray pneumonia (PN)-panel against standard culture in broncho-alveolar lavage (BAL) samples. Methods: Setting: University Hospital Basel (February 2019 to July 2020), including hospitalized patients with a BAL (± pneumonia). We determined sensitivity and specificity of the PN-panel against standard culture. Using univariate logistic regression, we calculated odds ratios (OR) for pneumonia according to PN-panel and culture status, stratifying by chronic pulmonary disease. We calculated ORs for pneumonia for different pathogens to estimate the clinical relevance. Results: We included 840 adult patients, 60% were males, median age was 68 years, 35% had chronic pulmonary disease, 21% had pneumonia, and 36% had recent antibiotic use. In 1078 BAL samples, bacterial pathogens were detected in 36% and 16% with PN-panel and culture, respectively. The overall sensitivity and specificity of the PN-panel was high, whereas the positive predictive value was low. The OR of pneumonia was 1.1 (95% CI 0.7–1.6) for PN-panel-positive only; 2.6 (95% CI 1.3–5.3) for culture-positive only, and 1.6 (95% CI 1.0–2.4) for PN-panel and culture-positive. The detection rate of Haemophilus influenzae, Staphylococcus aureus, and Moraxella catarrhalis in the PN-panel was high but not associated with pneumonia. Conclusion: While sensitivity and specificity of PN-panel are high compared to culture, pathogen detection did not correlate well with a pneumonia diagnosis. Patients with culture-positive BAL had the highest OR for pneumonia—thus the impact of the PN-panel on clinical management needs further evaluation in randomized controlled trials. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

111. Bacteremia During the First Year After Solid Organ Transplantation: An Epidemiological Update

Author

Neofytos, Dionysios, Stampf, Susanne, Hoessly, Linard D, D'Asaro, Matilde, Tang, Gael Nguyen, Boggian, Katia, Hirzel, Cedric, Khanna, Nina, Manuel, Oriol, Mueller, Nicolas J, and Van Delden, Christian

Subjects
610 Medicine & health
Abstract

BACKGROUND There are limited contemporary data on the epidemiology and outcomes of bacteremia in solid organ transplant recipients (SOTr). METHODS Using the Swiss Transplant Cohort Study registry from 2008 to 2019, we performed a retrospective nested multicenter cohort study to describe the epidemiology of bacteremia in SOTr during the first year post-transplant. RESULTS Of 4383 patients, 415 (9.5%) with 557 cases of bacteremia due to 627 pathogens were identified. One-year incidence was 9.5%, 12.8%, 11.4%, 9.8%, 8.3%, and 5.9% for all, heart, liver, lung, kidney, and kidney-pancreas SOTr, respectively (P = .003). Incidence decreased during the study period (hazard ratio, 0.66; P < .001). One-year incidence due to gram-negative bacilli (GNB), gram-positive cocci (GPC), and gram-positive bacilli (GPB) was 5.62%, 2.81%, and 0.23%, respectively. Seven (of 28, 25%) Staphylococcus aureus isolates were methicillin-resistant, 2/67 (3%) enterococci were vancomycin-resistant, and 32/250 (12.8%) GNB produced extended-spectrum beta-lactamases. Risk factors for bacteremia within 1 year post-transplant included age, diabetes, cardiopulmonary diseases, surgical/medical post-transplant complications, rejection, and fungal infections. Predictors for bacteremia during the first 30 days post-transplant included surgical post-transplant complications, rejection, deceased donor, and liver and lung transplantation. Transplantation in 2014-2019, CMV donor-negative/recipient-negative serology, and cotrimoxazole Pneumocystis prophylaxis were protective against bacteremia. Thirty-day mortality in SOTr with bacteremia was 3% and did not differ by SOT type. CONCLUSIONS Almost 1/10 SOTr may develop bacteremia during the first year post-transplant associated with low mortality. Lower bacteremia rates have been observed since 2014 and in patients receiving cotrimoxazole prophylaxis. Variabilities in incidence, timing, and pathogen of bacteremia across different SOT types may be used to tailor prophylactic and clinical approaches.

Published
2023

112. Toxoplasmosis in Transplant Recipients, Europe, 2010-2014

Author

Robert-Gangneux, Florence, Meroni, Valeria, Dupont, Damien, Botterel, Frangoise, Garcia, Jose M. Aguado, Brenier- Pinchart, Marie-Pierre, Accoceberry, Isabelle, Akan, Hamdi, Abbate, Isabella, Boggian, Katia, Bruschi, Fabrizio, Carratala, Jordi, David, Miruna, Drgona, Lubos, Djurkovic-Djakovic, Olgica, Farinas, Maria Carmen, Genco, Francesca, Gkrania-Klotsas, Effrossyni, Groll, Andreas H., Guy, Edward, Hirzel, Cedric, Khanna, Nina, Kurt, Ozgur, Junie, Lia Monica, Lazzarotto, Tiziana, Len, Oscar, Mueller, Nicolas J., Munoz, Patricia, Pana, Zoi Dorothea, Roilides, Emmanuel, Stajner, Tijana, van Delden, Christian, Villena, Isabelle, Pelloux, Herve, and Manuel, Oriol

Subjects
Toxoplasmosis -- Health aspects, Hematopoietic stem cell transplantation -- Health aspects, Stem cells -- Health aspects, Organ transplantation -- Health aspects, Liver -- Health aspects, Health
Abstract

Toxoplasmosis is a zoonosis that infects humans and other warm-blooded animals worldwide; prevalence and clinical severity vary by geographic area (1). After primary infection, the parasite persists lifelong within dormant [...]

Published
2018
Full Text
View/download PDF

115. A Clean Energy Korea by 2035

Author

Park, Won Young, Park, Won Young, Abhyankar, Nikit, Paliwal, Umed, Kim, James, Khanna, Nina, Shiraishi, Kenji, Lin, Jiang, Phadke, Amol, Song, Yong Hyun, Moon, Hee Seung, Kim, Eunsung, Hong, Sanghyun, Kim, Seung Wan, Park, Won Young, Park, Won Young, Abhyankar, Nikit, Paliwal, Umed, Kim, James, Khanna, Nina, Shiraishi, Kenji, Lin, Jiang, Phadke, Amol, Song, Yong Hyun, Moon, Hee Seung, Kim, Eunsung, Hong, Sanghyun, and Kim, Seung Wan

Abstract

The current global energy crisis has massive implications for the people and economy of South Korea (Korea), where at least 90% of energy use depends on foreign fossil fuels. Clean electricity accounts for only 39% of total generation, with electricity demand expected to increase 30% by 2035. This study shows that Korea can achieve 80% clean electricity by 2035 by capitalizing on rapid technological improvements and decreasing costs of solar, wind, and battery technology. Doing so would slightly lower electricity supply costs, significantly reduce dependence on imported natural gas and coal, and dramatically cut power sector emissions. Further, this study finds that Korea’s power grid under a clean energy scenario will maintain reliability without coal generation or new natural gas plants. To realize these significant economic, environmental, and energy security benefits, policies such as an 80% clean electricity standard by 2035 and corresponding renewable energy deployment goals are required.

Published
2023

116. European candidaemia is characterised by notable differential epidemiology and susceptibility pattern:Results from the ECMM Candida III study

Author

Arendrup, Maiken Cavling, Arikan-Akdagli, Sevtap, Jørgensen, Karin Meinike, Barac, Aleksandra, Steinmann, Jörg, Toscano, Cristina, Arsenijevic, Valentina Arsic, Sartor, Assunta, Lass-Flörl, Cornelia, Hamprecht, Axel, Matos, Tadeja, Rogers, Benedict R.S., Quiles, Inmaculada, Buil, Jochem, Özenci, Volkan, Krause, Robert, Bassetti, Matteo, Loughlin, Laura, Denis, Blandine, Grancini, Anna, White, P. Lewis, Lagrou, Katrien, Willinger, Birgit, Rautemaa-Richardson, Riina, Hamal, Petr, Ener, Beyza, Unalan-Altintop, Tugce, Evren, Ebru, Hilmioglu-Polat, Suleyha, Oz, Yasemin, Ozyurt, Ozlem Koyuncu, Aydin, Faruk, Růžička, Filip, Meijer, Eelco F.J., Gangneux, Jean Pierre, Lockhart, Deborah E.A., Khanna, Nina, Logan, Clare, Scharmann, Ulrike, Desoubeaux, Guillaume, Roilides, Emmanuel, Talento, Alida Fe, van Dijk, Karin, Koehler, Philipp, Salmanton-García, Jon, Cornely, Oliver A., Hoenigl, Martin, Arendrup, Maiken Cavling, Arikan-Akdagli, Sevtap, Jørgensen, Karin Meinike, Barac, Aleksandra, Steinmann, Jörg, Toscano, Cristina, Arsenijevic, Valentina Arsic, Sartor, Assunta, Lass-Flörl, Cornelia, Hamprecht, Axel, Matos, Tadeja, Rogers, Benedict R.S., Quiles, Inmaculada, Buil, Jochem, Özenci, Volkan, Krause, Robert, Bassetti, Matteo, Loughlin, Laura, Denis, Blandine, Grancini, Anna, White, P. Lewis, Lagrou, Katrien, Willinger, Birgit, Rautemaa-Richardson, Riina, Hamal, Petr, Ener, Beyza, Unalan-Altintop, Tugce, Evren, Ebru, Hilmioglu-Polat, Suleyha, Oz, Yasemin, Ozyurt, Ozlem Koyuncu, Aydin, Faruk, Růžička, Filip, Meijer, Eelco F.J., Gangneux, Jean Pierre, Lockhart, Deborah E.A., Khanna, Nina, Logan, Clare, Scharmann, Ulrike, Desoubeaux, Guillaume, Roilides, Emmanuel, Talento, Alida Fe, van Dijk, Karin, Koehler, Philipp, Salmanton-García, Jon, Cornely, Oliver A., and Hoenigl, Martin

Abstract

The objectives of this study were to assess Candida spp. distribution and antifungal resistance of candidaemia across Europe. Isolates were collected as part of the third ECMM Candida European multicentre observational study, conducted from 01 to 07-07-2018 to 31-03-2022. Each centre (maximum number/country determined by population size) included ∼10 consecutive cases. Isolates were referred to central laboratories and identified by morphology and MALDI-TOF, supplemented by ITS-sequencing when needed. EUCAST MICs were determined for five antifungals. fks sequencing was performed for echinocandin resistant isolates. The 399 isolates from 41 centres in 17 countries included C. albicans (47.1%), C. glabrata (22.3%), C. parapsilosis (15.0%), C. tropicalis (6.3%), C. dubliniensis and C. krusei (2.3% each) and other species (4.8%). Austria had the highest C. albicans proportion (77%), Czech Republic, France and UK the highest C. glabrata proportions (25–33%) while Italy and Turkey had the highest C. parapsilosis proportions (24–26%). All isolates were amphotericin B susceptible. Fluconazole resistance was found in 4% C. tropicalis, 12% C. glabrata (from six countries across Europe), 17% C. parapsilosis (from Greece, Italy, and Turkey) and 20% other Candida spp. Four isolates were anidulafungin and micafungin resistant/non-wild-type and five resistant to micafungin only. Three/3 and 2/5 of these were sequenced and harboured fks-alterations including a novel L657W in C. parapsilosis. The epidemiology varied among centres and countries. Acquired echinocandin resistance was rare but included differential susceptibility to anidulafungin and micafungin, and resistant C. parapsilosis. Fluconazole and voriconazole cross-resistance was common in C. glabrata and C. parapsilosis but with different geographical prevalence., The objectives of this study were to assess Candida spp. distribution and antifungal resistance of candidaemia across Europe. Isolates were collected as part of the third ECMM Candida European multicentre observational study, conducted from 01 to 07-07-2018 to 31-03-2022. Each centre (maximum number/country determined by population size) included ∼10 consecutive cases. Isolates were referred to central laboratories and identified by morphology and MALDI-TOF, supplemented by ITS-sequencing when needed. EUCAST MICs were determined for five antifungals. fks sequencing was performed for echinocandin resistant isolates. The 399 isolates from 41 centres in 17 countries included C. albicans (47.1%), C. glabrata (22.3%), C. parapsilosis (15.0%), C. tropicalis (6.3%), C. dubliniensis and C. krusei (2.3% each) and other species (4.8%). Austria had the highest C. albicans proportion (77%), Czech Republic, France and UK the highest C. glabrata proportions (25–33%) while Italy and Turkey had the highest C. parapsilosis proportions (24–26%). All isolates were amphotericin B susceptible. Fluconazole resistance was found in 4% C. tropicalis, 12% C. glabrata (from six countries across Europe), 17% C. parapsilosis (from Greece, Italy, and Turkey) and 20% other Candida spp. Four isolates were anidulafungin and micafungin resistant/non-wild-type and five resistant to micafungin only. Three/3 and 2/5 of these were sequenced and harboured fks-alterations including a novel L657W in C. parapsilosis. The epidemiology varied among centres and countries. Acquired echinocandin resistance was rare but included differential susceptibility to anidulafungin and micafungin, and resistant C. parapsilosis. Fluconazole and voriconazole cross-resistance was common in C. glabrata and C. parapsilosis but with different geographical prevalence.

Published
2023

117. COVID-19 in adult acute myeloid leukemia patients:a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)

Author

Marchesi, Francesco, Salmanton-García, Jon, Emarah, Ziad, Piukovics, Klára, Nucci, Marcio, López-García, Alberto, Ráčil, Zdeněk, Farina, Francesca, Popova, Marina, Zompi, Sofia, Audisio, Ernesta, Ledoux, Marie Pierre, Verga, Luisa, Weinbergerová, Barbora, Szotkovski, Tomas, Da Silva, Maria Gomes, Fracchiolla, Nicola, De Jonge, Nick, Collins, Graham, Marchetti, Monia, Magliano, Gabriele, García-Vidal, Carolina, Biernat, Monika M., Van Doesum, Jaap, Machado, Marina, Demirkan, Fatih, Al-Khabori, Murtadha, Žák, Pavel, Víšek, Benjamín, Stoma, Igor, Méndez, Gustavo Adolfo, Maertens, Johan, Khanna, Nina, Espigado, Ildefonso, Dragonetti, Giulia, Fianchi, Luana, Del Principe, Maria Ilaria, Cabirta, Alba, Ormazabal-Vélez, Irati, Jaksic, Ozren, Buquicchio, Caterina, Bonuomo, Valentina, Batinić, Josip, Omrani, Ali S., Lamure, Sylvain, Finizio, Olimpia, Fernández, Noemí, Falces-Romero, Iker, Blennow, Ola, Bergantim, Rui, Ali, Natasha, Win, Sein, Van Praet, Jens, Tisi, Maria Chiara, Shirinova, Ayten, Schönlein, Martin, Prattes, Juergen, Piedimonte, Monica, Petzer, Verena, Navrátil, Milan, Kulasekararaj, Austin, Jindra, Pavel, Sramek, Jiří, Glenthøj, Andreas, Fazzi, Rita, De Ramón-Sánchez, Cristina, Cattaneo, Chiara, Calbacho, Maria, Bahr, Nathan C., El-Ashwah, Shaimaa, Cordoba, Raul, Hanakova, Michaela, Zambrotta, Giovanni Paolo Maria, Zambrotta, Giovanni, Sciumè, Mariarita, Booth, Stephen, Rodrigues, Raquel Nunes, Sacchi, Maria Vittoria, García-Poutón, Nicole, Martín-González, Juan Alberto, Khostelidi, Sofya, Gräfe, Stefanie, Rahimli, Laman, Ammatuna, Emanuele, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Cornely, Oliver A., Pagano, Livio, Marchesi, Francesco, Salmanton-García, Jon, Emarah, Ziad, Piukovics, Klára, Nucci, Marcio, López-García, Alberto, Ráčil, Zdeněk, Farina, Francesca, Popova, Marina, Zompi, Sofia, Audisio, Ernesta, Ledoux, Marie Pierre, Verga, Luisa, Weinbergerová, Barbora, Szotkovski, Tomas, Da Silva, Maria Gomes, Fracchiolla, Nicola, De Jonge, Nick, Collins, Graham, Marchetti, Monia, Magliano, Gabriele, García-Vidal, Carolina, Biernat, Monika M., Van Doesum, Jaap, Machado, Marina, Demirkan, Fatih, Al-Khabori, Murtadha, Žák, Pavel, Víšek, Benjamín, Stoma, Igor, Méndez, Gustavo Adolfo, Maertens, Johan, Khanna, Nina, Espigado, Ildefonso, Dragonetti, Giulia, Fianchi, Luana, Del Principe, Maria Ilaria, Cabirta, Alba, Ormazabal-Vélez, Irati, Jaksic, Ozren, Buquicchio, Caterina, Bonuomo, Valentina, Batinić, Josip, Omrani, Ali S., Lamure, Sylvain, Finizio, Olimpia, Fernández, Noemí, Falces-Romero, Iker, Blennow, Ola, Bergantim, Rui, Ali, Natasha, Win, Sein, Van Praet, Jens, Tisi, Maria Chiara, Shirinova, Ayten, Schönlein, Martin, Prattes, Juergen, Piedimonte, Monica, Petzer, Verena, Navrátil, Milan, Kulasekararaj, Austin, Jindra, Pavel, Sramek, Jiří, Glenthøj, Andreas, Fazzi, Rita, De Ramón-Sánchez, Cristina, Cattaneo, Chiara, Calbacho, Maria, Bahr, Nathan C., El-Ashwah, Shaimaa, Cordoba, Raul, Hanakova, Michaela, Zambrotta, Giovanni Paolo Maria, Zambrotta, Giovanni, Sciumè, Mariarita, Booth, Stephen, Rodrigues, Raquel Nunes, Sacchi, Maria Vittoria, García-Poutón, Nicole, Martín-González, Juan Alberto, Khostelidi, Sofya, Gräfe, Stefanie, Rahimli, Laman, Ammatuna, Emanuele, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Cornely, Oliver A., and Pagano, Livio

Abstract

Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80%; P<0.001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs. 60% vs. 61.9%, respectively; P=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible.

Published
2023

118. Outcome of COVID-19 in allogeneic stem cell transplant recipients:Results from the EPICOVIDEHA registry

Author

Busca, Alessandro, Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Seval, Guldane Cengiz, Van Doesum, Jaap, De Jonge, Nick, Bahr, Nathan C., Maertens, Johan, Meletiadis, Joseph, Fracchiolla, Nicola S., Weinbergerová, Barbora, Verga, Luisa, Ráčil, Zdeněk, Jiménez, Moraima, Glenthøj, Andreas, Blennow, Ola, Tanase, Alina Daniela, Schönlein, Martin, Prezioso, Lucia, Khanna, Nina, Duarte, Rafael F., Žák, Pavel, Nucci, Marcio, Machado, Marina, Kulasekararaj, Austin, Espigado, Ildefonso, De Kort, Elizabeth, Ribera-Santa Susana, José María, Marchetti, Monia, Magliano, Gabriele, Falces-Romero, Iker, Ilhan, Osman, Ammatuna, Emanuele, Zompi, Sofia, Tsirigotis, Panagiotis, Antoniadou, Anastasia, Zambrotta, Giovanni Paolo Maria, Nordlander, Anna, Karlsson, Linda Katharina, Hanakova, Michaela, Dragonetti, Giulia, Cabirta, Alba, Berg Venemyr, Caroline, Gräfe, Stefanie, Van Praet, Jens, Tragiannidis, Athanasios, Petzer, Verena, López-García, Alberto, Itri, Federico, Groh, Ana, Gavriilaki, Eleni, Dargenio, Michelina, Rahimli, Laman, Cornely, Oliver A., Pagano, Livio, Busca, Alessandro, Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Seval, Guldane Cengiz, Van Doesum, Jaap, De Jonge, Nick, Bahr, Nathan C., Maertens, Johan, Meletiadis, Joseph, Fracchiolla, Nicola S., Weinbergerová, Barbora, Verga, Luisa, Ráčil, Zdeněk, Jiménez, Moraima, Glenthøj, Andreas, Blennow, Ola, Tanase, Alina Daniela, Schönlein, Martin, Prezioso, Lucia, Khanna, Nina, Duarte, Rafael F., Žák, Pavel, Nucci, Marcio, Machado, Marina, Kulasekararaj, Austin, Espigado, Ildefonso, De Kort, Elizabeth, Ribera-Santa Susana, José María, Marchetti, Monia, Magliano, Gabriele, Falces-Romero, Iker, Ilhan, Osman, Ammatuna, Emanuele, Zompi, Sofia, Tsirigotis, Panagiotis, Antoniadou, Anastasia, Zambrotta, Giovanni Paolo Maria, Nordlander, Anna, Karlsson, Linda Katharina, Hanakova, Michaela, Dragonetti, Giulia, Cabirta, Alba, Berg Venemyr, Caroline, Gräfe, Stefanie, Van Praet, Jens, Tragiannidis, Athanasios, Petzer, Verena, López-García, Alberto, Itri, Federico, Groh, Ana, Gavriilaki, Eleni, Dargenio, Michelina, Rahimli, Laman, Cornely, Oliver A., and Pagano, Livio

Abstract

Background: The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. Methods: This multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. Results: The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). Conclusions: Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.

Published
2023

119. COVID-19 in adult acute myeloid leukemia patients: a long-term follow-up study from the European Hematology Association survey (EPICOVIDEHA)

Author

Marchesi, Francesco, Salmanton-García, Jon, Emarah, Ziad, Piukovics, Klára, Nucci, Marcio, López-García, Alberto, Ráčil, Zdeněk, Farina, Francesca, Popova, Marina, Zompi, Sofia, Audisio, Ernesta, Ledoux, Marie-Pierre, Verga, Luisa, Weinbergerová, Barbora, Szotkovski, Toma, Da Silva, Maria Gome, Fracchiolla, Nicola, De Jonge, Nick, Collins, Graham, Marchetti, Monia, Magliano, Gabriele, García-Vidal, Carolina, Biernat, Monika M, Van Doesum, Jaap, Machado, Marina, Demirkan, Fatih, Al-Khabori, Murtadha, Žák, Pavel, Víšek, Benjamín, Stoma, Igor, Méndez, Gustavo-Adolfo, Maertens, Johan, Khanna, Nina, Espigado, Ildefonso, Dragonetti, Giulia, Fianchi, Luana, Del Principe, Maria Ilaria, Cabirta, Alba, Ormazabal-Vélez, Irati, Jaksic, Ozren, Buquicchio, Caterina, Bonuomo, Valentina, Batinić, Josip, Omrani, Ali S, Lamure, Sylvain, Finizio, Olimpia, Fernández, Noemí, Falces-Romero, Iker, Blennow, Ola, Bergantim, Rui, Ali, Natasha, Win, Sein, Van Praet, Jen, Tisi, Maria Chiara, Shirinova, Ayten, Schönlein, Martin, Prattes, Juergen, Piedimonte, Monica, Petzer, Verena, Navrátil, Milan, Kulasekararaj, Austin, Jindra, Pavel, Sramek, Jiří, Glenthøj, Andrea, Fazzi, Rita, De Ramón-Sánchez, Cristina, Cattaneo, Chiara, Calbacho, Maria, Bahr, Nathan C, El-Ashwah, Shaimaa, Cordoba, Raul, Hanakova, Michaela, Zambrotta, Giovanni, Sciumè, Mariarita, Booth, Stephen, Rodrigues, Raquel Nune, Sacchi, Maria Vittoria, García-Poutón, Nicole, Martín-González, Juan-Alberto, Khostelidi, Sofya, Gräfe, Stefanie, Rahimli, Laman, Ammatuna, Emanuele, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Cornely, Oliver A, Pagano, Livio, Pagano, Livio (ORCID:0000-0001-8287-928X), Marchesi, Francesco, Salmanton-García, Jon, Emarah, Ziad, Piukovics, Klára, Nucci, Marcio, López-García, Alberto, Ráčil, Zdeněk, Farina, Francesca, Popova, Marina, Zompi, Sofia, Audisio, Ernesta, Ledoux, Marie-Pierre, Verga, Luisa, Weinbergerová, Barbora, Szotkovski, Toma, Da Silva, Maria Gome, Fracchiolla, Nicola, De Jonge, Nick, Collins, Graham, Marchetti, Monia, Magliano, Gabriele, García-Vidal, Carolina, Biernat, Monika M, Van Doesum, Jaap, Machado, Marina, Demirkan, Fatih, Al-Khabori, Murtadha, Žák, Pavel, Víšek, Benjamín, Stoma, Igor, Méndez, Gustavo-Adolfo, Maertens, Johan, Khanna, Nina, Espigado, Ildefonso, Dragonetti, Giulia, Fianchi, Luana, Del Principe, Maria Ilaria, Cabirta, Alba, Ormazabal-Vélez, Irati, Jaksic, Ozren, Buquicchio, Caterina, Bonuomo, Valentina, Batinić, Josip, Omrani, Ali S, Lamure, Sylvain, Finizio, Olimpia, Fernández, Noemí, Falces-Romero, Iker, Blennow, Ola, Bergantim, Rui, Ali, Natasha, Win, Sein, Van Praet, Jen, Tisi, Maria Chiara, Shirinova, Ayten, Schönlein, Martin, Prattes, Juergen, Piedimonte, Monica, Petzer, Verena, Navrátil, Milan, Kulasekararaj, Austin, Jindra, Pavel, Sramek, Jiří, Glenthøj, Andrea, Fazzi, Rita, De Ramón-Sánchez, Cristina, Cattaneo, Chiara, Calbacho, Maria, Bahr, Nathan C, El-Ashwah, Shaimaa, Cordoba, Raul, Hanakova, Michaela, Zambrotta, Giovanni, Sciumè, Mariarita, Booth, Stephen, Rodrigues, Raquel Nune, Sacchi, Maria Vittoria, García-Poutón, Nicole, Martín-González, Juan-Alberto, Khostelidi, Sofya, Gräfe, Stefanie, Rahimli, Laman, Ammatuna, Emanuele, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Cornely, Oliver A, Pagano, Livio, and Pagano, Livio (ORCID:0000-0001-8287-928X)

Abstract

Patients with acute myeloid leukemia (AML) are at high risk of dying from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients diagnosed with COVID-19 between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the preceding 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with better survival when AML treatment could be delayed (80%; P<0.001). Overall survival in patients with a diagnosis of COVID-19 between January 2020 and August 2020 was significantly lower than that in patients diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs. 60% vs. 61.9%, respectively; P=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible.

Published
2023

120. COVID-19 in adult acute myeloid leukemia patients: a long-term followup study from the European Hematology Association survey (EPICOVIDEHA)

Author

Gilead Sciences, Marchesi, Francesco, Salmanton-García, Jon, Emarah, Ziad, Piukovics, Klára, Nucci, Marcio, López-García, Alberto, Ráčil, Zdeněk, Farina, Francesca, Popova, Marina, Zompi, Sofia, Audisio, Ernesta, Ledoux, Marie-Pierre, Verga, Luisa, Weinbergerová, Barbora, Szotkovski, Tomas, Gomes-Silva, Maria, Fracchiolla, Nicola S., Jonge, Nick de, Collins, Graham P., Marchetti, Monia, Magliano, Gabriel, García-Vidal, Carolina, Biernat, Monika, Doesum, Jaap van, Machado, Marina, Demirkan, Fatih, Al-Khabori, Murtadha, Žák, Pavel, Víšek, Benjamin, Stoma, Igor, Méndez, Gustavo-Adolfo, Maertens, Johan, Khanna, Nina, Espigado, Ildefonso, Dragonetti, Giulia, Fianchi, Luana, Príncipe, María Ilaria del, Cabirta, Alba, Ormazabal-Vélez, Irati, Jakšić, Ozren, Buquicchio, Caterina, Bonuomo, Valentina, Batinić, Josip, Omrani, Ali S., Lamure, Sylvain, Finizio, Olimpia, Fernández, Noemí, Falces-Romero, Iker, Blennow, Ola, Bergantim, Rui, Ali, Natasha, Win, Sein, Praet, Jens van, Tisi, Maria Chiara, Shirinova, Ayten, Schönlein, Martin, Prattes, Juergen, Piedimonte, Monica, Petzer, Verena, Navrátil, Milan, Kulasekararaj, Austin G., Jindra, Pavel, Sramek, Jiří, Glenthøj, Andrea, Fazzi, Rita, Ramón, Cristina de, Cattaneo, Chiara, Calbacho, María, Bahr, Nathan C., El-Ashwah, Shaimaa, Córdoba, Raúl, Hanakova, Michaela, Zambrotta, Giovanni, Sciumè, Mariarita, Booth, Stephen, Nunes-Rodrigues, Raquel, Sacchi, Maria Vittoria, García-Poutón, Nicole, Martín-González, Juan-Alberto, Khostelidi, Sofya, Gräfe, Stefanie, Rahimli, Laman, Ammatuna, Emanuele, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolay, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Cornely, Oliver A., Pagano, Livio, Gilead Sciences, Marchesi, Francesco, Salmanton-García, Jon, Emarah, Ziad, Piukovics, Klára, Nucci, Marcio, López-García, Alberto, Ráčil, Zdeněk, Farina, Francesca, Popova, Marina, Zompi, Sofia, Audisio, Ernesta, Ledoux, Marie-Pierre, Verga, Luisa, Weinbergerová, Barbora, Szotkovski, Tomas, Gomes-Silva, Maria, Fracchiolla, Nicola S., Jonge, Nick de, Collins, Graham P., Marchetti, Monia, Magliano, Gabriel, García-Vidal, Carolina, Biernat, Monika, Doesum, Jaap van, Machado, Marina, Demirkan, Fatih, Al-Khabori, Murtadha, Žák, Pavel, Víšek, Benjamin, Stoma, Igor, Méndez, Gustavo-Adolfo, Maertens, Johan, Khanna, Nina, Espigado, Ildefonso, Dragonetti, Giulia, Fianchi, Luana, Príncipe, María Ilaria del, Cabirta, Alba, Ormazabal-Vélez, Irati, Jakšić, Ozren, Buquicchio, Caterina, Bonuomo, Valentina, Batinić, Josip, Omrani, Ali S., Lamure, Sylvain, Finizio, Olimpia, Fernández, Noemí, Falces-Romero, Iker, Blennow, Ola, Bergantim, Rui, Ali, Natasha, Win, Sein, Praet, Jens van, Tisi, Maria Chiara, Shirinova, Ayten, Schönlein, Martin, Prattes, Juergen, Piedimonte, Monica, Petzer, Verena, Navrátil, Milan, Kulasekararaj, Austin G., Jindra, Pavel, Sramek, Jiří, Glenthøj, Andrea, Fazzi, Rita, Ramón, Cristina de, Cattaneo, Chiara, Calbacho, María, Bahr, Nathan C., El-Ashwah, Shaimaa, Córdoba, Raúl, Hanakova, Michaela, Zambrotta, Giovanni, Sciumè, Mariarita, Booth, Stephen, Nunes-Rodrigues, Raquel, Sacchi, Maria Vittoria, García-Poutón, Nicole, Martín-González, Juan-Alberto, Khostelidi, Sofya, Gräfe, Stefanie, Rahimli, Laman, Ammatuna, Emanuele, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolay, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Cornely, Oliver A., and Pagano, Livio

Abstract

Patients with acute myeloid leukemia (AML) are at high risk of mortality from coronavirus disease 2019 (COVID-19). The optimal management of AML patients with COVID-19 has not been established. Our multicenter study included 388 adult AML patients with COVID-19 diagnosis between February 2020 and October 2021. The vast majority were receiving or had received AML treatment in the prior 3 months. COVID-19 was severe in 41.2% and critical in 21.1% of cases. The chemotherapeutic schedule was modified in 174 patients (44.8%), delayed in 68 and permanently discontinued in 106. After a median follow-up of 325 days, 180 patients (46.4%) had died; death was attributed to COVID-19 (43.3%), AML (26.1%) or to a combination of both (26.7%), whereas in 3.9% of cases the reason was unknown. Active disease, older age, and treatment discontinuation were associated with death, whereas AML treatment delay was protective. Seventy-nine patients had a simultaneous AML and COVID-19 diagnosis, with an improved survival when AML treatment could be delayed (80%; p<0.001). Overall survival in patients with COVID-19 diagnosis between January 2020 and August 2020 was significantly lower than those who were diagnosed between September 2020 and February 2021 and between March 2021 and September 2021 (39.8% vs 60% vs 61.9%, respectively; p=0.006). COVID-19 in AML patients was associated with a high mortality rate and modifications of therapeutic algorithms. The best approach to improve survival was to delay AML treatment, whenever possible.

Published
2023

121. Guideline adherence and survival of patients with candidaemia in Europe: results from the ECMM Candida III multinational European observational cohort study

Author

Scynexis, Hoenigl, Martin, Salmanton-García, Jon, Egger, Matthias, Gangneux, Jean-Pierre, Bicanic, Tihana, Arikan-Akdagli, Sevtap, Alastruey-Izquierdo, Ana, Klimko, Nikolai, Barac, Aleksandra, Özenci, Volkan, Meijer, Eelco F. J., Khanna, Nina, Bassetti, Matteo, Rautemaa-Richardson, Riina, Lagrou, Katrien, Adam, Kai-Manuel, Akalin, Emin Halis, Akova, Murat, Arsic-Arsenijevic, Valentina, Aujayeb, Avinash, Blennow, Ola, Bretagne, Stéphane, Danion, François, Denis, Blandine, Jonge, Nick de, Desoubeaux, Guillaume, Drgona, Lubos, Erben, Nurettin, Gori, Andrea, García-Rodríguez, Julio, García-Vidal, Carolina, Giacobbe, Daniele Roberto, Goodman, Anna L., Hamal, Petr, Hammarström, Helena, Toscano, Cristina, Lanternier, Fanny, Lass-Flörl, Cornelia, Lockhart, Deborah E. A., Longval, Thomas, Loughlin, Laura, Matos, Tadeja, Mikulska, Malgorzata, Narayanan, Manjusha, Martín-Pérez, Sonia, Prattes, Juergen, Rogers, Benedict, Rahimli, Laman, Ruiz, Maite, Roilides, Emmanuel, Samarkos, Michael, Scharmann, Ulrike, Sili, Uluhan, Sipahi, Oguz Resat, Sivakova, Alena, Steinmann, Joerg, Trauth, Janina, Turhan, Ozge, Praet, Jens van, Vena, Antonio, White, P. Lewis, Willinger, Birgit, Tortorano, Anna Maria, Arendrup, Maiken C., Koehler, Philipp, Cornely, Oliver A., ECMM Candida III Study Group, Scynexis, Hoenigl, Martin, Salmanton-García, Jon, Egger, Matthias, Gangneux, Jean-Pierre, Bicanic, Tihana, Arikan-Akdagli, Sevtap, Alastruey-Izquierdo, Ana, Klimko, Nikolai, Barac, Aleksandra, Özenci, Volkan, Meijer, Eelco F. J., Khanna, Nina, Bassetti, Matteo, Rautemaa-Richardson, Riina, Lagrou, Katrien, Adam, Kai-Manuel, Akalin, Emin Halis, Akova, Murat, Arsic-Arsenijevic, Valentina, Aujayeb, Avinash, Blennow, Ola, Bretagne, Stéphane, Danion, François, Denis, Blandine, Jonge, Nick de, Desoubeaux, Guillaume, Drgona, Lubos, Erben, Nurettin, Gori, Andrea, García-Rodríguez, Julio, García-Vidal, Carolina, Giacobbe, Daniele Roberto, Goodman, Anna L., Hamal, Petr, Hammarström, Helena, Toscano, Cristina, Lanternier, Fanny, Lass-Flörl, Cornelia, Lockhart, Deborah E. A., Longval, Thomas, Loughlin, Laura, Matos, Tadeja, Mikulska, Malgorzata, Narayanan, Manjusha, Martín-Pérez, Sonia, Prattes, Juergen, Rogers, Benedict, Rahimli, Laman, Ruiz, Maite, Roilides, Emmanuel, Samarkos, Michael, Scharmann, Ulrike, Sili, Uluhan, Sipahi, Oguz Resat, Sivakova, Alena, Steinmann, Joerg, Trauth, Janina, Turhan, Ozge, Praet, Jens van, Vena, Antonio, White, P. Lewis, Willinger, Birgit, Tortorano, Anna Maria, Arendrup, Maiken C., Koehler, Philipp, Cornely, Oliver A., and ECMM Candida III Study Group

Abstract

[Background] The European Confederation of Medical Mycology (ECMM) collected data on epidemiology, risk factors, treatment, and outcomes of patients with culture-proven candidaemia across Europe to assess how adherence to guideline recommendations is associated with outcomes., [Methods] In this observational cohort study, 64 participating hospitals located in 20 European countries, with the number of eligible hospitals per country determined by population size, included the first ten consecutive adults with culture-proven candidaemia after July 1, 2018, and entered data into the ECMM Candida Registry (FungiScope CandiReg). We assessed ECMM Quality of Clinical Candidaemia Management (EQUAL Candida) scores reflecting adherence to recommendations of the European Society of Clinical Microbiology and Infectious Diseases and the Infectious Diseases Society of America guidelines., [Findings] 632 patients with candidaemia were included from 64 institutions. Overall 90-day mortality was 43% (265/617), and increasing age, intensive care unit admission, point increases in the Charlson comorbidity index score, and Candida tropicalis as causative pathogen were independent baseline predictors of mortality in Cox regression analysis. EQUAL Candida score remained an independent predictor of mortality in the multivariable Cox regression analyses after adjusting for the baseline predictors, even after restricting the analysis to patients who survived for more than 7 days after diagnosis (adjusted hazard ratio 1·08 [95% CI 1·04–1·11; p<0·0001] in patients with a central venous catheter and 1·09 [1·05–1·13; p<0·0001] in those without one, per one score point decrease). Median duration of hospital stay was 15 days (IQR 4–30) after diagnosis of candidaemia and was extended specifically for completion of parenteral therapy in 100 (16%) of 621 patients. Initial echinocandin treatment was associated with lower overall mortality and longer duration of hospital stay among survivors than treatment with other antifungals., [Interpretation] Although overall mortality in patients with candidaemia was high, our study indicates that adherence to clinical guideline recommendations, reflected by higher EQUAL Candida scores, might increase survival. New antifungals, with similar activity as current echinocandins but with longer half-lives or oral bioavailability, are needed to reduce duration of hospital stay.

Published
2023

122. Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

Author

Gilead Sciences, Busca, Alessandro, Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Cengiz-Seval, Guldane, Doesum, Jaap van, Jonge, Nick de, Bahr, Nathan C., Maertens, Johan, Meletiadis, Joseph, Fracchiolla, Nicola S., Weinbergerová, Barbora, Verga, Luisa, Ráčil, Zdeněk, Jiménez, Moraima, Glenthøj, Andreas, Blennow, Ola, Tanase, Alina Daniela, Schönlein, Martin, Prezioso, Lucia, Khanna, Nina, Duarte, Rafael F., Žák, Pavel, Nucci, Marcio, Machado, Marina, Kulasekararaj, Austin, Espigado, Ildefonso, Kort, Elizabeth de, Ribera-Santa Susana, José-María, Marchetti, Monia, Magliano, Gabriele, Falces-Romero, Iker, Ilhan, Osman, Ammatuna, Emanuele, Zompi, Sofia, Tsirigotis, Panagiotis, Antoniadou, Anastasia, Zambrotta, Giovanni Paolo Maria, Nordlander, Anna, Karlsson, Linda Katharina, Hanakova, Michaela, Dragonetti, Giulia, Cabirta, Alba, Berg Venemyr, Caroline, Gräfe, Stefanie, Praet, Jens van, Tragiannidis, Athanasios, Petzer, Verena, López-García, Alberto, Itri, Federico, Groh, Ana, Gavriilaki, Eleni, Dargenio, Michelina, Rahimli, Laman, Cornely, Oliver A., Pagano, Livio, EPICOVIDEHA Consortium, Gilead Sciences, Busca, Alessandro, Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Cengiz-Seval, Guldane, Doesum, Jaap van, Jonge, Nick de, Bahr, Nathan C., Maertens, Johan, Meletiadis, Joseph, Fracchiolla, Nicola S., Weinbergerová, Barbora, Verga, Luisa, Ráčil, Zdeněk, Jiménez, Moraima, Glenthøj, Andreas, Blennow, Ola, Tanase, Alina Daniela, Schönlein, Martin, Prezioso, Lucia, Khanna, Nina, Duarte, Rafael F., Žák, Pavel, Nucci, Marcio, Machado, Marina, Kulasekararaj, Austin, Espigado, Ildefonso, Kort, Elizabeth de, Ribera-Santa Susana, José-María, Marchetti, Monia, Magliano, Gabriele, Falces-Romero, Iker, Ilhan, Osman, Ammatuna, Emanuele, Zompi, Sofia, Tsirigotis, Panagiotis, Antoniadou, Anastasia, Zambrotta, Giovanni Paolo Maria, Nordlander, Anna, Karlsson, Linda Katharina, Hanakova, Michaela, Dragonetti, Giulia, Cabirta, Alba, Berg Venemyr, Caroline, Gräfe, Stefanie, Praet, Jens van, Tragiannidis, Athanasios, Petzer, Verena, López-García, Alberto, Itri, Federico, Groh, Ana, Gavriilaki, Eleni, Dargenio, Michelina, Rahimli, Laman, Cornely, Oliver A., Pagano, Livio, and EPICOVIDEHA Consortium

Abstract

Background: The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. Methods: This multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. Results: The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). Conclusions: Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection.

Published
2023

123. Bacteremia During the First Year After Solid Organ Transplantation: An Epidemiological Update

Author

Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, Stampf, Susanne, Hoessly, Linard D, D'Asaro, Matilde, Tang, Gael Nguyen, Boggian, Katia, Hirzel, Cedric, Khanna, Nina; https://orcid.org/0000-0002-2642-419X, Manuel, Oriol, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Van Delden, Christian, Swiss Transplant Cohort Study, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, Stampf, Susanne, Hoessly, Linard D, D'Asaro, Matilde, Tang, Gael Nguyen, Boggian, Katia, Hirzel, Cedric, Khanna, Nina; https://orcid.org/0000-0002-2642-419X, Manuel, Oriol, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Van Delden, Christian, and Swiss Transplant Cohort Study

Abstract

BACKGROUND: There are limited contemporary data on the epidemiology and outcomes of bacteremia in solid organ transplant recipients (SOTr). METHODS: Using the Swiss Transplant Cohort Study registry from 2008 to 2019, we performed a retrospective nested multicenter cohort study to describe the epidemiology of bacteremia in SOTr during the first year post-transplant. RESULTS: Of 4383 patients, 415 (9.5%) with 557 cases of bacteremia due to 627 pathogens were identified. One-year incidence was 9.5%, 12.8%, 11.4%, 9.8%, 8.3%, and 5.9% for all, heart, liver, lung, kidney, and kidney-pancreas SOTr, respectively (P = .003). Incidence decreased during the study period (hazard ratio, 0.66; P < .001). One-year incidence due to gram-negative bacilli (GNB), gram-positive cocci (GPC), and gram-positive bacilli (GPB) was 5.62%, 2.81%, and 0.23%, respectively. Seven (of 28, 25%) Staphylococcus aureus isolates were methicillin-resistant, 2/67 (3%) enterococci were vancomycin-resistant, and 32/250 (12.8%) GNB produced extended-spectrum beta-lactamases. Risk factors for bacteremia within 1 year post-transplant included age, diabetes, cardiopulmonary diseases, surgical/medical post-transplant complications, rejection, and fungal infections. Predictors for bacteremia during the first 30 days post-transplant included surgical post-transplant complications, rejection, deceased donor, and liver and lung transplantation. Transplantation in 2014-2019, CMV donor-negative/recipient-negative serology, and cotrimoxazole Pneumocystis prophylaxis were protective against bacteremia. Thirty-day mortality in SOTr with bacteremia was 3% and did not differ by SOT type. CONCLUSIONS: Almost 1/10 SOTr may develop bacteremia during the first year post-transplant associated with low mortality. Lower bacteremia rates have been observed since 2014 and in patients receiving cotrimoxazole prophylaxis. Variabilities in incidence, timing, and pathogen of bacteremia across different SOT types may be used to tailo

Published
2023

124. Vaccine-Preventable Infections Among Solid Organ Transplant Recipients in Switzerland

Author

Walti, Laura N, Mugglin, Catrina, Mombelli, Matteo, Manuel, Oriol, Hirsch, Hans H, Khanna, Nina, Mueller, Nicolas J, Berger, Christoph, Boggian, Katia, Garzoni, Christian, Neofytos, Dionysios, van Delden, Christian, Mäusezahl, Mirjam, Hirzel, Cédric, Swiss Transplant Cohort Study, Walti, Laura N, Mugglin, Catrina, Mombelli, Matteo, Manuel, Oriol, Hirsch, Hans H, Khanna, Nina, Mueller, Nicolas J, Berger, Christoph, Boggian, Katia, Garzoni, Christian, Neofytos, Dionysios, van Delden, Christian, Mäusezahl, Mirjam, Hirzel, Cédric, and Swiss Transplant Cohort Study

Abstract

IMPORTANCE Vaccine responses are decreased in solid organ transplant (SOT) recipients, and given the complexity of implementation, vaccination programs may be suboptimal. The actual burden of vaccine-preventable infections (VPIs) among SOT recipients remains unclear. OBJECTIVES To assess the incidence rate of VPIs among SOT recipients and to evaluate whether SOT recipients are at increased risk for specific VPIs compared with the general population. DESIGN, SETTING, AND PARTICIPANTS This nationwide cohort study used data from the Swiss Transplant Cohort Study on VPIs in individuals who underwent SOT from May 2008 to June 2019 (follow-up until December 2019) and data from the Swiss Federal Office of Public Health on notifiable VPIs in the general population in the same period. Data were analyzed from January 2021 to June 2022. EXPOSURES Solid organ transplant. MAIN OUTCOMES AND MEASURES The main outcomes were the incidence rate of the following VPIs in SOT recipients: hepatitis A and B, diphtheria, Haemophilus influenzae infection, influenza, measles, mumps, pertussis, pneumococcal disease, poliomyelitis, meningococcal disease, rubella, tetanus, tick-borne encephalitis, and varicella zoster virus infection. Age-adjusted standardized incidence ratios were used to assess whether VPIs occurred more frequently in SOT recipients compared with the general population. For SOT recipients, factors associated with occurrence of VPIs were explored and the associated morbidity and mortality assessed. RESULTS Of 4967 SOT recipients enrolled (median age, 54 years [IQR, 42-62 years]; 3191 [64.2%] male), 593 (11.9%) experienced at least 1 VPI. The overall VPI incidence rate was higher in the population that underwent SOT (30.57 per 1000 person-years [PY]; 95% CI, 28.24-33.10 per 1000 PY) compared with the general population (0.71 per 1000 PY). The standardized age-adjusted incidence ratio for notifiable VPIs in SOT recipients was higher compared with the general population (27.84; 9

Published
2023

125. Bloodstream infections in allogeneic haematopoietic cell recipients from the Swiss Transplant Cohort Study: trends of causative pathogens and resistance rates

Author

Sava, Mihaela; https://orcid.org/0000-0001-5763-9073, Bättig, Veronika; https://orcid.org/0000-0002-7418-977X, Gerull, Sabine; https://orcid.org/0000-0002-6612-4220, Passweg, Jakob R; https://orcid.org/0000-0001-7092-3351, Khanna, Nina; https://orcid.org/0000-0002-2642-419X, Garzoni, Christian; https://orcid.org/0000-0002-0832-2376, Gerber, Bernhard; https://orcid.org/0000-0003-1708-8558, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Schanz, Urs, Berger, Christoph; https://orcid.org/0000-0002-1730-8824, Chalandon, Yves; https://orcid.org/0000-0001-9341-8104, van Delden, Christian; https://orcid.org/0000-0002-2901-8285, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, Stampf, Susanne; https://orcid.org/0000-0003-3399-5078, Franzeck, Fabian C; https://orcid.org/0000-0001-7510-0231, Weisser, Maja; https://orcid.org/0000-0002-0134-1929, Sava, Mihaela; https://orcid.org/0000-0001-5763-9073, Bättig, Veronika; https://orcid.org/0000-0002-7418-977X, Gerull, Sabine; https://orcid.org/0000-0002-6612-4220, Passweg, Jakob R; https://orcid.org/0000-0001-7092-3351, Khanna, Nina; https://orcid.org/0000-0002-2642-419X, Garzoni, Christian; https://orcid.org/0000-0002-0832-2376, Gerber, Bernhard; https://orcid.org/0000-0003-1708-8558, Mueller, Nicolas J; https://orcid.org/0000-0002-1059-3191, Schanz, Urs, Berger, Christoph; https://orcid.org/0000-0002-1730-8824, Chalandon, Yves; https://orcid.org/0000-0001-9341-8104, van Delden, Christian; https://orcid.org/0000-0002-2901-8285, Neofytos, Dionysios; https://orcid.org/0000-0001-6970-2869, Stampf, Susanne; https://orcid.org/0000-0003-3399-5078, Franzeck, Fabian C; https://orcid.org/0000-0001-7510-0231, and Weisser, Maja; https://orcid.org/0000-0002-0134-1929

Published
2023

126. Guideline adherence and survival of patients with candidaemia in Europe:results from the ECMM Candida III multinational European observational cohort study

Author

Hoenigl, Martin, Salmanton-García, Jon, Egger, Matthias, Gangneux, Jean-Pierre, Bicanic, Tihana, Arikan-Akdagli, Sevtap, Alastruey-Izquierdo, Ana, Klimko, Nikolai, Barac, Aleksandra, Özenci, Volkan, Meijer, Eelco F. J., Khanna, Nina, Bassetti, Matteo, Rautemaa-Richardson, Riina, Lagrou, Katrien, Adam, Kai Manuel, Akalin, Emin Halis, Akova, Murat, Arsenijevic, Valentina Arsic, Aujayeb, Avinash, Blennow, Ola, Bretagne, Stéphane, Danion, François, Denis, Blandine, de Jonge, Nick Alexander, Desoubeaux, Guillaume, Drgona, Lubos, Erben, Nurettin, Gori, Andrea, García Rodríguez, Julio, Garcia-Vidal, Carolina, Giacobbe, Daniele Roberto, Goodman, Anna L., Hamal, Petr, Hammarström, Helena, Toscano, Cristina, Lanternier, Fanny, Lass-Flörl, Cornelia, Lockhart, Deborah E. A., Longval, Thomas, Loughlin, Laura, Matos, Tadeja, Mikulska, Malgorzata, Narayanan, Manjusha, Martín-Pérez, Sonia, Prattes, Juergen, Rogers, Benedict, Rahimli, Laman, Ruiz, Maite, Roilides, Emmanuel, Samarkos, Michael, Scharmann, Ulrike, Sili, Uluhan, Sipahi, Oguz Resat, Sivakova, Alena, Steinmann, Joerg, Trauth, Janina, Turhan, Ozge, Van Praet, Jens, Vena, Antonio, White, P. Lewis, Willinger, Birgit, Tortorano, Anna Maria, Arendrup, Maiken C., Koehler, Philipp, Cornely, Oliver A., Hoenigl, Martin, Salmanton-García, Jon, Egger, Matthias, Gangneux, Jean-Pierre, Bicanic, Tihana, Arikan-Akdagli, Sevtap, Alastruey-Izquierdo, Ana, Klimko, Nikolai, Barac, Aleksandra, Özenci, Volkan, Meijer, Eelco F. J., Khanna, Nina, Bassetti, Matteo, Rautemaa-Richardson, Riina, Lagrou, Katrien, Adam, Kai Manuel, Akalin, Emin Halis, Akova, Murat, Arsenijevic, Valentina Arsic, Aujayeb, Avinash, Blennow, Ola, Bretagne, Stéphane, Danion, François, Denis, Blandine, de Jonge, Nick Alexander, Desoubeaux, Guillaume, Drgona, Lubos, Erben, Nurettin, Gori, Andrea, García Rodríguez, Julio, Garcia-Vidal, Carolina, Giacobbe, Daniele Roberto, Goodman, Anna L., Hamal, Petr, Hammarström, Helena, Toscano, Cristina, Lanternier, Fanny, Lass-Flörl, Cornelia, Lockhart, Deborah E. A., Longval, Thomas, Loughlin, Laura, Matos, Tadeja, Mikulska, Malgorzata, Narayanan, Manjusha, Martín-Pérez, Sonia, Prattes, Juergen, Rogers, Benedict, Rahimli, Laman, Ruiz, Maite, Roilides, Emmanuel, Samarkos, Michael, Scharmann, Ulrike, Sili, Uluhan, Sipahi, Oguz Resat, Sivakova, Alena, Steinmann, Joerg, Trauth, Janina, Turhan, Ozge, Van Praet, Jens, Vena, Antonio, White, P. Lewis, Willinger, Birgit, Tortorano, Anna Maria, Arendrup, Maiken C., Koehler, Philipp, and Cornely, Oliver A.

Abstract

Background: The European Confederation of Medical Mycology (ECMM) collected data on epidemiology, risk factors, treatment, and outcomes of patients with culture-proven candidaemia across Europe to assess how adherence to guideline recommendations is associated with outcomes. Methods: In this observational cohort study, 64 participating hospitals located in 20 European countries, with the number of eligible hospitals per country determined by population size, included the first ten consecutive adults with culture-proven candidaemia after July 1, 2018, and entered data into the ECMM Candida Registry (FungiScope CandiReg). We assessed ECMM Quality of Clinical Candidaemia Management (EQUAL Candida) scores reflecting adherence to recommendations of the European Society of Clinical Microbiology and Infectious Diseases and the Infectious Diseases Society of America guidelines. Findings: 632 patients with candidaemia were included from 64 institutions. Overall 90-day mortality was 43% (265/617), and increasing age, intensive care unit admission, point increases in the Charlson comorbidity index score, and Candida tropicalis as causative pathogen were independent baseline predictors of mortality in Cox regression analysis. EQUAL Candida score remained an independent predictor of mortality in the multivariable Cox regression analyses after adjusting for the baseline predictors, even after restricting the analysis to patients who survived for more than 7 days after diagnosis (adjusted hazard ratio 1·08 [95% CI 1·04–1·11; p<0·0001] in patients with a central venous catheter and 1·09 [1·05–1·13; p<0·0001] in those without one, per one score point decrease). Median duration of hospital stay was 15 days (IQR 4–30) after diagnosis of candidaemia and was extended specifically for completion of parenteral therapy in 100 (16%) of 621 patients. Initial echinocandin treatment was associated with lower overall mortality and longer duration of hospital stay among survivors than t

Published
2023

127. Policy Brief: Climate change impacts of plastics

Author

Scientists' Coalition for an Effective Plastics Treaty, Karali, Nihan, Palm, Ellen, Baztan, Juan, Gomes, Patricia Villarubia, Khanna, Nina, Kvale, Karin, Lacerda, Ana Luzia, and Jorgenson, Bethany

Abstract

This Policy brief delves into the ways in which plastics production and consumptioncontributes to the emissions of greenhouse gases throughout the plastic product lifecycle. The document is an output of the Scientists' Coalition for an Effective Plastics Treaty (SCEPT) working group on climate change impacts,and aims at policymakers involved in the Intergovernmental Negotiation Committee (INC). A French and Spanish version of the brief will be available soon.

Published
2023
Full Text
View/download PDF

129. Reply to Cunha et al

Author

Swiss Transplant Cohort Study, Wójtowicz, Agnieszka, Lecompte, Thanh Doco, Bibert, Stéphanie, Manuel, Oriol, Rüeger, Sina, Berger, Christoph, Boggian, Katia, Cusini, Alexia, Garzoni, Christian, Khanna, Nina, Mueller, Nicolas J., Meylan, Pascal R., Pascual, Manuel, van Delden, Christian, and Bochud, Pierre-Yves

Published
2015
Full Text
View/download PDF

130. New Treatment Options for Refractory/Resistant CMV Infection.

Author

Simone Walti, Carla, Khanna, Nina, Avery, Robin K., and Helanterä, Ilkka

Subjects
*CYTOMEGALOVIRUS diseases, *REFRACTORY materials, *T cells, *CELLULAR therapy, *TRANSPLANTATION of organs, tissues, etc.
Abstract

Despite advances in monitoring and treatment, cytomegalovirus (CMV) infections remain one of the most common complications after solid organ transplantation (SOT). CMV infection may fail to respond to standard first- and second-line antiviral therapies with or without the presence of antiviral resistance to these therapies. This failure to respond after 14 days of appropriate treatment is referred to as "resistant/refractory CMV." Limited data on refractory CMV without antiviral resistance are available. Reported rates of resistant CMV are up to 18% in SOT recipients treated for CMV. Therapeutic options for treating these infections are limited due to the toxicity of the agent used or transplant-related complications. This is often the challenge with conventional agents such as ganciclovir, foscarnet and cidofovir. Recent introduction of new CMV agents including maribavir and letermovir as well as the use of adoptive T cell therapy may improve the outcome of these difficult-to-treat infections in SOT recipients. In this expert review, we focus on new treatment options for resistant/refractory CMV infection and disease in SOT recipients, with an emphasis on maribavir, letermovir, and adoptive T cell therapy. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

133. Epidemiology and outcomes of bone and joint infections in solid organ transplant recipients

Author

Pham, Truong-Thanh, primary, Andrey, Diego O., additional, Stampf, Susanne, additional, Burkhard, Sara H., additional, Hirzel, Cédric, additional, Tschopp, Johnathan, additional, Ullrich, Kathrin, additional, Strahm, Carol, additional, Schreiber, Peter W., additional, Boillat-Blanco, Noémie, additional, Garzoni, Christian, additional, Khanna, Nina, additional, Manuel, Oriol, additional, Mueller, Nicolas J., additional, Suva, Domizio, additional, van Delden, Christian, additional, Uçkay, Ilker, additional, and Neofytos, Dionysios, additional

Published
2022
Full Text
View/download PDF

134. Outcome of COVID-19 in allogeneic stem cell transplant recipients: Results from the EPICOVIDEHA registry

Author

Busca, Alessandro, Salmanton-García, Jon, Marchesi, Francesco, Farina, Francesca, Seval, Guldane Cengiz, Van Doesum, Jaap, De Jonge, Nick, Bahr, Nathan C., Maertens, Johan, Meletiadis, Joseph, Fracchiolla, Nicola S., Weinbergerová, Barbora, Verga, Luisa, Ráčil, Zdeněk, Jiménez, Moraima, Glenthøj, Andreas, Blennow, Ola, Tanase, Alina Daniela, Schönlein, Martin, Prezioso, Lucia, Khanna, Nina, Duarte, Rafael F., Žák, Pavel, Nucci, Marcio, Machado, Marina, Kulasekararaj, Austin, Espigado, Ildefonso, De Kort, Elizabeth, Ribera-Santa Susana, José-María, Marchetti, Monia, Magliano, Gabriele, Falces-Romero, Iker, Ilhan, Osman, Ammatuna, Emanuele, Zompi, Sofia, Tsirigotis, Panagiotis, Antoniadou, Anastasia, Zambrotta, Giovanni Paolo Maria, Nordlander, Anna, Karlsson, Linda Katharina, Hanakova, Michaela, Dragonetti, Giulia, Cabirta, Alba, Berg Venemyr, Caroline, Gräfe, Stefanie, Van Praet, Jens, Tragiannidis, Athanasios, Petzer, Verena, López-García, Alberto, Itri, Federico, Groh, Ana, Gavriilaki, Eleni, Dargenio, Michelina, Rahimli, Laman, Cornely, Oliver A., Pagano, Livio, EPICOVIDEHA Consortium, [missing], Hematology, Institut Català de la Salut, [Busca A] Stem Cell Transplant Center, AOU Citta’ della Salute e della Scienza, Turin, Italy. [Salmanton-García J] University of Cologne, Faculty of Medicine and University Hospital Cologne, Translational Research, Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), Cologne, Germany. University of Cologne, Faculty of Medicine and University Hospital Cologne, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf (CIO ABCD) and Excellence Center for Medical Mycology (ECMM), Cologne, Germany. [Marchesi F] Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. [Farina F] IRCCS Ospedale San Raffaele, Milan, Italy. [Seval GC] Ankara University, Ankara, Türkiye. [Van Doesum J] University Medical Center Groningen, Groningen, Netherlands. [Jiménez M] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
hematological malignances, Cèl·lules mare hematopoètiques - Trasplantació, SARS-CoV-2, Hemic and Lymphatic Diseases::Hematologic Diseases [DISEASES], Immunology, allogeneic HSCT, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], COVID-19 (Malaltia), COVID-19 infection, Cancer development and immune defence Radboud Institute for Health Sciences [Radboudumc 2], enfermedades hematológicas y linfáticas::enfermedades hematológicas [ENFERMEDADES], Settore MED/15 - MALATTIE DEL SANGUE, All institutes and research themes of the Radboud University Medical Center, Allogeneic HSCT, Sang - Malalties, immunocompromised patients, Medicine and Health Sciences, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Hematological malignances, Immunocompromised patients, Immunology and Allergy, Therapeutics::Biological Therapy::Cell- and Tissue-Based Therapy::Cell Transplantation::Stem Cell Transplantation::Hematopoietic Stem Cell Transplantation [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], terapéutica::terapia biológica::tratamientos basados en células y tejidos::trasplante de células::trasplante de células madre::trasplante de células madre hematopoyéticas [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS]
Abstract

COVID-19 infection; Hematological malignances; Immunocompromised patients Infecció per COVID-19; Neoplasies hematològiques; Pacients immunodeprimits Infección por COVID-19; Neoplasias hematológicas; Pacientes inmunodeprimidos Background: The outcome of COVID-19 in allogeneic hematopoietic stem cell transplantation (HSCT) recipients is almost uniformely considered poor. The aim of present study was to retrospectively analyse the outcome and risk factors for mortality in a large series of patients who developed COVID-19 infection after an allogeneic HSCT. Methods: This multicenter retrospective study promoted by the European Hematology Association – Infections in Hematology Study Working Group, included 326 adult HSCT patients who had COVID-19 between January 2020 and March 2022. Results: The median time from HSCT to the diagnosis of COVID-19 was 268 days (IQR 86-713; range 0-185 days). COVID-19 severity was mild in 21% of the patients, severe in 39% and critical in 16% of the patients. In multivariable analysis factors associated with a higher risk of mortality were, age above 50 years, presence of 3 or more comorbidities, active hematologic disease at time of COVID-19 infection, development of COVID-19 within 12 months of HSCT, and severe/critical infections. Overall mortality rate was 21% (n=68): COVID-19 was the main or secondary cause of death in 16% of the patients (n=53). Conclusions: Mortality in HSCT recipients who develop COVID-19 is high and largely dependent on age, comorbidities, active hematologic disease, timing from transplant and severity of the infection. EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223). The funder of the study had no role in study design, data analysis, interpretation, or writing of the report. All authors had full access to the data and had final responsibility for the decision to submit for publication.

Published
2023

135. Correction to: Catheter retention as a consequence rather than a cause of unfavorable outcome in candidemia

Author

Damonti, Lauro, Erard, Véronique, Garbino, Jorge, Schrenzel, Jacques, Zimmerli, Stefan, Mühlethaler, Konrad, Imhof, Alexander, Zbinden, Reinhard, Fehr, Jan, Boggian, Katia, Bruderer, Thomas, Flückiger, Ursula, Frei, Reno, Orasch, Christina, Conen, Anna, Khanna, Nina, Bregenzer, Thomas, Bille, Jacques, Lamoth, Frédéric, Marchetti, Oscar, Bochud, Pierre-Yves, and Fungal Infection Network of Switzerland (FUNGINOS)

Published
2018
Full Text
View/download PDF

136. Catheter retention as a consequence rather than a cause of unfavorable outcome in candidemia

Author

Damonti, Lauro, Erard, Véronique, Garbino, Jorge, Schrenzel, Jacques, Zimmerli, Stefan, Mühlethaler, Konrad, Imhof, Alexander, Zbinden, Reinhard, Fehr, Jan, Boggian, Katia, Bruderer, Thomas, Flückiger, Ursula, Frei, Reno, Orasch, Christina, Conen, Anna, Khanna, Nina, Bregenzer, Thomas, Bille, Jacques, Lamoth, Frédéric, Marchetti, Oscar, Bochud, Pierre-Yves, and Fungal Infection Network of Switzerland (FUNGINOS)

Published
2017
Full Text
View/download PDF

142. A lipoglycopeptide antibiotic for Gram-positive biofilm-related infections

Author

Blaskovich, Mark A. T., primary, Hansford, Karl A., additional, Butler, Mark S., additional, Ramu, Soumya, additional, Kavanagh, Angela M., additional, Jarrad, Angie M., additional, Prasetyoputri, Anggia, additional, Pitt, Miranda E., additional, Huang, Johnny X., additional, Lindahl, Fredrik, additional, Ziora, Zyta M., additional, Bradford, Tanya, additional, Muldoon, Craig, additional, Rajaratnam, Premraj, additional, Pelingon, Ruby, additional, Edwards, David J., additional, Zhang, Bing, additional, Amado, Maite, additional, Elliott, Alysha G., additional, Zuegg, Johannes, additional, Coin, Lachlan, additional, Woischnig, Anne-Kathrin, additional, Khanna, Nina, additional, Breidenstein, Elena, additional, Stincone, Anna, additional, Mason, Clive, additional, Khan, Nawaz, additional, Cho, Hye-Kyung, additional, Karau, Melissa J., additional, Greenwood-Quaintance, Kerryl E., additional, Patel, Robin, additional, Wootton, Mandy, additional, James, Meagan L., additional, Hutton, Melanie L., additional, Lyras, Dena, additional, Ogunniyi, Abiodun D., additional, Mahdi, Layla K., additional, Trott, Darren J., additional, Wu, Xiaoqian, additional, Niles, Samantha, additional, Lewis, Kim, additional, Smith, Jordan R., additional, Barber, Katie E., additional, Yim, Juwon, additional, Rice, Seth Alan, additional, Rybak, Michael J., additional, Ishmael, Chad R., additional, Hori, Kellyn R., additional, Bernthal, Nicholas M., additional, Francis, Kevin P., additional, Roberts, Jason A., additional, Paterson, David L., additional, and Cooper, Matthew A., additional

Published
2022
Full Text
View/download PDF

143. Characterization of pathogen‐inactivated COVID ‐19 convalescent plasma and responses in transfused patients

Author

Weisser, Maja, primary, Khanna, Nina, additional, Hedstueck, Anemone, additional, Sutter, Sarah Tschudin, additional, Roesch, Sandra, additional, Stehle, Gregor, additional, Sava, Mihaela, additional, Deigendesch, Nikolaus, additional, Battegay, Manuel, additional, Infanti, Laura, additional, Holbro, Andreas, additional, Bassetti, Stefano, additional, Pargger, Hans, additional, Hirsch, Hans H., additional, Leuzinger, Karoline, additional, Kaiser, Laurent, additional, Vu, Diem‐Lan, additional, Baur, Katharina, additional, Massaro, Nadine, additional, Busch, Michael Paul, additional, Simmons, Graham, additional, Stone, Mars, additional, Felgner, Philip L., additional, de Assis, Rafael R., additional, Khan, Saahir, additional, Tsai, Cheng‐ting, additional, Robinson, Peter V., additional, Seftel, David, additional, Irsch, Johannes, additional, Bagri, Anil, additional, Buser, Andreas S., additional, and Corash, Laurence, additional

Published
2022
Full Text
View/download PDF

146. Distribution of Aspergillus Species and Prevalence of Azole Resistance in Respiratory Samples From Swiss Tertiary Care Hospitals

Author

Ragozzino, Silvio, Goldenberger, Daniel, Wright, Patrick R, Zimmerli, Stefan, Mühlethaler, Konrad, Neofytos, Dionysios, Riat, Arnaud, Boggian, Katia, Nolte, Oliver, Conen, Anna, Fankhauser, Hans, Schreiber, Peter W, Zbinden, Reinhard, Lamoth, Frederic, Khanna, Nina, University of Zurich, and Khanna, Nina

Subjects
ddc:616, TR34/L98H mutation, Aspergillus fumigatus, Cyp51A gene, 610 Medicine & health, bacterial infections and mycoses, azole resistance, cyp51A gene, non-fumigatus Aspergillus spp, 10234 Clinic for Infectious Diseases, 2728 Neurology (clinical), Infectious Diseases, Oncology, Azole resistance, 2730 Oncology, skin and connective tissue diseases, Non-fumigatus Aspergillus spp
Abstract

Among 400 Aspergillus species from respiratory samples in Switzerland, Aspergillus fumigatus was the most frequent species. Non-fumigatus Aspergillus spp were more prevalent among solid organ transplant recipients and after azole exposure. Azole resistance was detected in 4 A fumigatus isolates, 3 of them with the “environmental” mutation TR34/L98H in the cyp51A gene.

Published
2022

147. COVID-19 infection in adult patients with hematological malignancies: a European Hematology Association Survey (EPICOVIDEHA)

Author

Gilead Sciences, Pagano, Livio [0000-0001-8287-928X], Salmanton-García, Jon [0000-0002-6766-8297], Marchesi, Francesco [0000-0001-6353-2272], Busca, Alessandro [0000-0001-5361-5613], Corradini, Paolo [0000-0002-9186-1353], Hoenigl, Martin [0000-0002-1653-2824], Klimko, Nikolay [0000-0001-6095-7531], Koehler, Philipp [0000-0002-7386-7495], Pagliuca, Antonio [0000-0003-2519-0333], Passamonti, Francesco [0000-0001-8068-5289], Verga, Luisa [0000-0003-1142-8435], Víšek, Benjamin [0000-0001-8268-452X], Ilhan, Osman [0000-0003-1665-372X], Weinbergerová, Barbora [0000-0001-6460-2471], Córdoba, Raúl [0000-0002-7654-8836], Marchetti, Monia [0000-0001-7615-0572], Farina, Francesca [0000-0002-5124-6970], Cattaneo, Chiara [0000-0003-0031-3237], Cabirta, Alba [0000-0001-7198-8894], Gomes-Silva, Maria [0000-0002-6993-2450], Itri, Federico [0000-0002-3532-5281], Doesum, Jaap van [0000-0003-0214-3219], Ledoux, Marie-Pierre [0000-0002-3261-3616], Čerňan, Martin [0000-0003-2345-1229], Jakšić, Ozren [0000-0003-4026-285X], Magliano, Gabriel [0000-0002-9129-1530], Omrani, Ali S. [0000-0001-5309-6358], Fracchiolla, Nicola S. [0000-0002-8982-8079], Kulasekararaj, Austin G. [0000-0003-3180-3570], Valković, Toni [0000-0001-6083-8815], Poulsen, Christian Bjørn [0000-0001-9785-1378], Machado, Marina [0000-0002-8370-2248], Glenthøj, Andrea [0000-0003-2082-0738], Stoma, Igor [0000-0003-0483-7329], Ráčil, Zdeněk [0000-0003-3511-4596], Piukovics, Klára [0000-0003-4480-3131], Emarah, Ziad [0000-0003-0622-2598], Sili, Uluhan [0000-0002-9939-9298], Maertens, Johan [0000-0003-4257-5980], Bergantim, Rui [0000-0002-7811-9509], García-Vidal, Carolina [0000-0002-8915-0683], Prezioso, Lucia [0000-0003-1660-4960], Principe, Maria Ilaria del [0000-0002-3958-0669], Popova, Marina [0000-0001-8536-5495], Jonge, Nick de [0000-0002-9901-0887], Ormazabal-Vélez, Irati [0000-0003-1141-5546], Falces-Romero, Iker [0000-0001-5888-7706], Cuccaro, Annarosa [0000-0002-0237-1839], Meers, Stef [0000-0003-1754-2175], Buquicchio, Caterina [0000-0002-3683-5953], Antić, Darko [0000-0002-2608-1342], Al-Khabori, Murtadha [0000-0002-2937-8838], García-Sanz, Ramón [0000-0003-4120-2787], Biernat, Monika [0000-0003-3161-3398], Tisi, Maria Chiara [0000-0001-8231-6700], Sal, Ertan [0000-0003-2761-2675], Rahimli, Laman [0000-0003-2266-445X], Schönlein, Martin [0000-0002-1010-0975], Calbacho, María [0000-0001-8106-4863], Tascini, Carlo [0000-0001-9625-6024], Miranda-Castillo, Carolina [0000-0001-8763-9576], Khanna, Nina [0000-0002-2642-419X], Méndez, Gustavo-Adolfo [0000-0003-0514-7004], Petzer, Verena [0000-0002-9205-1440], Besson, Caroline [0000-0003-4364-7173], Duléry, Rémy [0000-0002-5024-1713], Lamure, Sylvain [0000-0001-5980-305X], Nucci, Marcio [0000-0003-4867-0014], Zambrotta, Giovanni [0000-0002-8612-2994], Žák, Pavel [0000-0003-4465-5343], Cengiz Seval, Guldane [0000-0001-9433-2054], Bonuomo, Valentina [0000-0001-6491-8337], Mayer, Jiří [0000-0003-0567-9887], López-García, Alberto [0000-0002-5354-5261], Sacchi, Maria Vittoria [0000-0001-8133-3357], Booth, Stephen [0000-0003-2687-0234], Ciceri, Fabio [0000-0003-0873-0123], Nunes-Rodrigues, Raquel [0000-0002-8347-4281], Ammatuna, Emanuele [0000-0001-8247-4901], Obr, Aleš [0000-0002-6758-3074], Herbrecht, Raoul [0000-0002-9381-4876], Shwaylia, Hawraa [0000-0002-4098-6092], Sciumè, Mariarita [0000-0001-7958-4966], Essame, Jenna [0000-0003-0926-5577], Batinić, Josip [0000-0001-5595-9911], Gonzaga, Yung [0000-0003-1416-2118], Regalado-Artamendi, Isabel [0000-0002-9673-9015], Karlsson, Linda Katharina [0000-0003-3317-7550], Shapetska, Maryia [0000-0002-1223-9161], El-Ashwah, Shaimaa [0000-0003-2210-1534], Çolak, Gökçe Melis [0000-0002-7662-7454], Dragonetti, Giulia [0000-0003-1775-6333], Rinaldi, Amelia [0000-0002-8211-5076], Ramón, Cristina de [0000-0002-8167-6410], Cornely, Oliver A. [0000-0001-9599-3137], Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolay, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Verga, Luisa, Gonzaga, Yung, Regalado-Artamendi, Isabel, Karlsson, Linda Katharina, Shapetska, Maryia, Hanakova, Michaela, El-Ashwah, Shaimaa, Borbényi, Zita, Çolak, Gökçe Melis, Nordlander, Anna, Dragonetti, Giulia, Víšek, Benjamin, Maraglino, Alessio Maria Edoardo, Rinaldi, Amelia, Ramón, Cristina de, Cornely, Oliver A., Ilhan, Osman, Nadali, Gianpaolo, Weinbergerová, Barbora, Córdoba, Raúl, Marchetti, Monia, Collins, Graham P., Farina, Francesca, Cattaneo, Chiara, Cabirta, Alba, Gomes-Silva, Maria, Itri, Federico, Doesum, Jaap van, Ledoux, Marie-Pierre, Čerňan, Martin, Jakšić, Ozren, Duarte, Rafael F., Magliano, Gabriel, Omrani, Ali S., Fracchiolla, Nicola S., Kulasekararaj, Austin G., Valković, Toni, Poulsen, Christian Bjørn, Machado, Marina, Glenthøj, Andrea, Stoma, Igor, Ráčil, Zdeněk, Piukovics, Klára, Navrátil, Milan, Emarah, Ziad, Sili, Uluhan, Maertens, Johan, Blennow, Ola, Bergantim, Rui, García-Vidal, Carolina, Prezioso, Lucia, Guidetti, Anna, Principe, Maria Ilaria del, Popova, Marina, Jonge, Nick de, Ormazabal-Vélez, Irati, Fernández, Noemí, Falces-Romero, Iker, Cuccaro, Annarosa, Meers, Stef, Buquicchio, Caterina, Antić, Darko, Al-Khabori, Murtadha, García-Sanz, Ramón, Biernat, Monika, Tisi, Maria Chiara, Sal, Ertan, Rahimli, Laman, Čolović, Natasa, Schönlein, Martin, Calbacho, María, Tascini, Carlo, Miranda-Castillo, Carolina, Khanna, Nina, Méndez, Gustavo-Adolfo, Petzer, Verena, Novák, Jan, Besson, Caroline, Duléry, Rémy, Lamure, Sylvain, Nucci, Marcio, Zambrotta, Giovanni, Žák, Pavel, Cengiz Seval, Guldane, Bonuomo, Valentina, Mayer, Jiří, López-García, Alberto, Sacchi, Maria Vittoria, Booth, Stephen, Ciceri, Fabio, Oberti, Margherita, Salvini, Marco, Izuzquiza, Macarena, Nunes-Rodrigues, Raquel, Ammatuna, Emanuele, Obr, Aleš, Herbrecht, Raoul, Núñez-Martín-Buitrago, Lucía, Mancini, Valentina, Shwaylia, Hawraa, Sciumè, Mariarita, Essame, Jenna, Nygaard, Marietta, Batinić, Josip, Gilead Sciences, Pagano, Livio [0000-0001-8287-928X], Salmanton-García, Jon [0000-0002-6766-8297], Marchesi, Francesco [0000-0001-6353-2272], Busca, Alessandro [0000-0001-5361-5613], Corradini, Paolo [0000-0002-9186-1353], Hoenigl, Martin [0000-0002-1653-2824], Klimko, Nikolay [0000-0001-6095-7531], Koehler, Philipp [0000-0002-7386-7495], Pagliuca, Antonio [0000-0003-2519-0333], Passamonti, Francesco [0000-0001-8068-5289], Verga, Luisa [0000-0003-1142-8435], Víšek, Benjamin [0000-0001-8268-452X], Ilhan, Osman [0000-0003-1665-372X], Weinbergerová, Barbora [0000-0001-6460-2471], Córdoba, Raúl [0000-0002-7654-8836], Marchetti, Monia [0000-0001-7615-0572], Farina, Francesca [0000-0002-5124-6970], Cattaneo, Chiara [0000-0003-0031-3237], Cabirta, Alba [0000-0001-7198-8894], Gomes-Silva, Maria [0000-0002-6993-2450], Itri, Federico [0000-0002-3532-5281], Doesum, Jaap van [0000-0003-0214-3219], Ledoux, Marie-Pierre [0000-0002-3261-3616], Čerňan, Martin [0000-0003-2345-1229], Jakšić, Ozren [0000-0003-4026-285X], Magliano, Gabriel [0000-0002-9129-1530], Omrani, Ali S. [0000-0001-5309-6358], Fracchiolla, Nicola S. [0000-0002-8982-8079], Kulasekararaj, Austin G. [0000-0003-3180-3570], Valković, Toni [0000-0001-6083-8815], Poulsen, Christian Bjørn [0000-0001-9785-1378], Machado, Marina [0000-0002-8370-2248], Glenthøj, Andrea [0000-0003-2082-0738], Stoma, Igor [0000-0003-0483-7329], Ráčil, Zdeněk [0000-0003-3511-4596], Piukovics, Klára [0000-0003-4480-3131], Emarah, Ziad [0000-0003-0622-2598], Sili, Uluhan [0000-0002-9939-9298], Maertens, Johan [0000-0003-4257-5980], Bergantim, Rui [0000-0002-7811-9509], García-Vidal, Carolina [0000-0002-8915-0683], Prezioso, Lucia [0000-0003-1660-4960], Principe, Maria Ilaria del [0000-0002-3958-0669], Popova, Marina [0000-0001-8536-5495], Jonge, Nick de [0000-0002-9901-0887], Ormazabal-Vélez, Irati [0000-0003-1141-5546], Falces-Romero, Iker [0000-0001-5888-7706], Cuccaro, Annarosa [0000-0002-0237-1839], Meers, Stef [0000-0003-1754-2175], Buquicchio, Caterina [0000-0002-3683-5953], Antić, Darko [0000-0002-2608-1342], Al-Khabori, Murtadha [0000-0002-2937-8838], García-Sanz, Ramón [0000-0003-4120-2787], Biernat, Monika [0000-0003-3161-3398], Tisi, Maria Chiara [0000-0001-8231-6700], Sal, Ertan [0000-0003-2761-2675], Rahimli, Laman [0000-0003-2266-445X], Schönlein, Martin [0000-0002-1010-0975], Calbacho, María [0000-0001-8106-4863], Tascini, Carlo [0000-0001-9625-6024], Miranda-Castillo, Carolina [0000-0001-8763-9576], Khanna, Nina [0000-0002-2642-419X], Méndez, Gustavo-Adolfo [0000-0003-0514-7004], Petzer, Verena [0000-0002-9205-1440], Besson, Caroline [0000-0003-4364-7173], Duléry, Rémy [0000-0002-5024-1713], Lamure, Sylvain [0000-0001-5980-305X], Nucci, Marcio [0000-0003-4867-0014], Zambrotta, Giovanni [0000-0002-8612-2994], Žák, Pavel [0000-0003-4465-5343], Cengiz Seval, Guldane [0000-0001-9433-2054], Bonuomo, Valentina [0000-0001-6491-8337], Mayer, Jiří [0000-0003-0567-9887], López-García, Alberto [0000-0002-5354-5261], Sacchi, Maria Vittoria [0000-0001-8133-3357], Booth, Stephen [0000-0003-2687-0234], Ciceri, Fabio [0000-0003-0873-0123], Nunes-Rodrigues, Raquel [0000-0002-8347-4281], Ammatuna, Emanuele [0000-0001-8247-4901], Obr, Aleš [0000-0002-6758-3074], Herbrecht, Raoul [0000-0002-9381-4876], Shwaylia, Hawraa [0000-0002-4098-6092], Sciumè, Mariarita [0000-0001-7958-4966], Essame, Jenna [0000-0003-0926-5577], Batinić, Josip [0000-0001-5595-9911], Gonzaga, Yung [0000-0003-1416-2118], Regalado-Artamendi, Isabel [0000-0002-9673-9015], Karlsson, Linda Katharina [0000-0003-3317-7550], Shapetska, Maryia [0000-0002-1223-9161], El-Ashwah, Shaimaa [0000-0003-2210-1534], Çolak, Gökçe Melis [0000-0002-7662-7454], Dragonetti, Giulia [0000-0003-1775-6333], Rinaldi, Amelia [0000-0002-8211-5076], Ramón, Cristina de [0000-0002-8167-6410], Cornely, Oliver A. [0000-0001-9599-3137], Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolay, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Verga, Luisa, Gonzaga, Yung, Regalado-Artamendi, Isabel, Karlsson, Linda Katharina, Shapetska, Maryia, Hanakova, Michaela, El-Ashwah, Shaimaa, Borbényi, Zita, Çolak, Gökçe Melis, Nordlander, Anna, Dragonetti, Giulia, Víšek, Benjamin, Maraglino, Alessio Maria Edoardo, Rinaldi, Amelia, Ramón, Cristina de, Cornely, Oliver A., Ilhan, Osman, Nadali, Gianpaolo, Weinbergerová, Barbora, Córdoba, Raúl, Marchetti, Monia, Collins, Graham P., Farina, Francesca, Cattaneo, Chiara, Cabirta, Alba, Gomes-Silva, Maria, Itri, Federico, Doesum, Jaap van, Ledoux, Marie-Pierre, Čerňan, Martin, Jakšić, Ozren, Duarte, Rafael F., Magliano, Gabriel, Omrani, Ali S., Fracchiolla, Nicola S., Kulasekararaj, Austin G., Valković, Toni, Poulsen, Christian Bjørn, Machado, Marina, Glenthøj, Andrea, Stoma, Igor, Ráčil, Zdeněk, Piukovics, Klára, Navrátil, Milan, Emarah, Ziad, Sili, Uluhan, Maertens, Johan, Blennow, Ola, Bergantim, Rui, García-Vidal, Carolina, Prezioso, Lucia, Guidetti, Anna, Principe, Maria Ilaria del, Popova, Marina, Jonge, Nick de, Ormazabal-Vélez, Irati, Fernández, Noemí, Falces-Romero, Iker, Cuccaro, Annarosa, Meers, Stef, Buquicchio, Caterina, Antić, Darko, Al-Khabori, Murtadha, García-Sanz, Ramón, Biernat, Monika, Tisi, Maria Chiara, Sal, Ertan, Rahimli, Laman, Čolović, Natasa, Schönlein, Martin, Calbacho, María, Tascini, Carlo, Miranda-Castillo, Carolina, Khanna, Nina, Méndez, Gustavo-Adolfo, Petzer, Verena, Novák, Jan, Besson, Caroline, Duléry, Rémy, Lamure, Sylvain, Nucci, Marcio, Zambrotta, Giovanni, Žák, Pavel, Cengiz Seval, Guldane, Bonuomo, Valentina, Mayer, Jiří, López-García, Alberto, Sacchi, Maria Vittoria, Booth, Stephen, Ciceri, Fabio, Oberti, Margherita, Salvini, Marco, Izuzquiza, Macarena, Nunes-Rodrigues, Raquel, Ammatuna, Emanuele, Obr, Aleš, Herbrecht, Raoul, Núñez-Martín-Buitrago, Lucía, Mancini, Valentina, Shwaylia, Hawraa, Sciumè, Mariarita, Essame, Jenna, Nygaard, Marietta, and Batinić, Josip

Abstract

Background Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value < 0.0001). In the multivariable analysis, age, active malignancy, chronic cardiac disease, liver disease, renal impairment, smoking history, and ICU stay correlated with mortality. Acute myeloid leukemia was a higher mortality risk than lymphoproliferative diseases. Conclusions This survey confirms that COVID-19 patients with HM are at high risk of lethal complications. However

Published
2021

150. COVID-19 infection in adult patients with hematological malignancies:a European Hematology Association Survey (EPICOVIDEHA)

Author

Pagano, Livio, Salmanton-García, Jon, Marchesi, Francesco, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Verga, Luisa, Víšek, Benjamin, Ilhan, Osman, Nadali, Gianpaolo, Weinbergerová, Barbora, Córdoba-Mascuñano, Raúl, Marchetti, Monia, Collins, Graham P., Farina, Francesca, Cattaneo, Chiara, Cabirta, Alba, Gomes-Silva, Maria, Itri, Federico, van Doesum, Jaap, Ledoux, Marie-Pierre, Čerňan, Martin, Jakšić, Ozren, Duarte, Rafael F., Magliano, Gabriele, Omrani, Ali S., Fracchiolla, Nicola S., Kulasekararaj, Austin, Valković, Toni, Poulsen, Christian Bjørn, Machado, Marina, Glenthøj, Andreas, Stoma, Igor, Ráčil, Zdeněk, Piukovics, Klára, Navrátil, Milan, Emarah, Ziad, Sili, Uluhan, Maertens, Johan, Blennow, Ola, Bergantim, Rui, García-Vidal, Carolina, Prezioso, Lucia, Guidetti, Anna, del Principe, Maria Ilaria, Popova, Marina, de Jonge, Nick, Ormazabal-Vélez, Irati, Fernández, Noemí, Falces-Romero, Iker, Cuccaro, Annarosa, Meers, Stef, Buquicchio, Caterina, Antić, Darko, Al-Khabori, Murtadha, García-Sanz, Ramón, Biernat, Monika M., Tisi, Maria Chiara, Sal, Ertan, Rahimli, Laman, Čolović, Natasa, Schönlein, Martin, Calbacho, Maria, Tascini, Carlo, Miranda-Castillo, Carolina, Khanna, Nina, Méndez, Gustavo-Adolfo, Petzer, Verena, Novák, Jan, Besson, Caroline, Duléry, Rémy, Lamure, Sylvain, Nucci, Marcio, Zambrotta, Giovanni, Žák, Pavel, Seval, Guldane Cengiz, Bonuomo, Valentina, Mayer, Jiří, López-García, Alberto, Sacchi, Maria Vittoria, Booth, Stephen, Ciceri, Fabio, Oberti, Margherita, Salvini, Marco, Izuzquiza, Macarena, Nunes-Rodrigues, Raquel, Ammatuna, Emanuele, Obr, Aleš, Herbrecht, Raoul, Núñez-Martín-Buitrago, Lucía, Mancini, Valentina, Shwaylia, Hawraa, Sciumè, Mariarita, Essame, Jenna, Nygaard, Marietta, Batinić, Josip, Gonzaga, Yung, Regalado-Artamendi, Isabel, Karlsson, Linda Katharina, Shapetska, Maryia, Hanakova, Michaela, El-Ashwah, Shaimaa, Borbényi, Zita, Çolak, Gökçe Melis, Nordlander, Anna, Dragonetti, Giulia, Maraglino, Alessio Maria Edoardo, Rinaldi, Amelia, De Ramón-Sánchez, Cristina, Cornely, Oliver A., Finizio, Olimpia, Fazzi, Rita, Sapienza, Giuseppe, Chauchet, Adrien, Van Praet, Jens, Prattes, Juergen, Dargenio, Michelina, Rossi, Cédric, Shirinova, Ayten, Malak, Sandra, Tafuri, Agostino, Ommen, Hans-Beier, Bologna, Serge, Khedr, Reham Abdelaziz, Choquet, Sylvain, Joly, Bertrand, Ceesay, M. Mansour, Philippe, Laure, Kho, Chi Shan, Desole, Maximilian, Tsirigotis, Panagiotis, Otašević, Vladimir, Borducchi, Davimar M. M., Antoniadou, Anastasia, Gaziev, Javid, Almaslamani, Muna A., García-Poutón, Nicole, Paterno, Giovangiacinto, Torres-López, Andrea, Tarantini, Giuseppe, Mellinghoff, Sibylle, Gräfe, Stefanie, Börschel, Niklas, Passweg, Jakob, Merelli, Maria, Barać, Aleksandra, Wolf, Dominik, Shaikh, Mohammad Usman, Thiéblemont, Catherine, Bernard, Sophie, Funke, Vaneuza Araújo Moreira, Daguindau, Etienne, Khostelidi, Sofya, Nucci, Fabio Moore, Martín-González, Juan-Alberto, Landau, Marianne, Soussain, Carole, Laureana, Cécile, Lacombe, Karine, Kohn, Milena, Aliyeva, Gunay, Piedimonte, Monica, Fouquet, Guillemette, Rêgo, Mayara, Hoell-Neugebauer, Baerbel, Cartron, Guillaume, Pinto, Fernando, Alburquerque, Ana Munhoz, Passos, Juliana, Yilmaz, Asu Fergun, Redondo-Izal, Ana-Margarita, Altuntaş, Fevzi, Heath, Christopher, Kolditz, Martin, Schalk, Enrico, Guolo, Fabio, Karthaus, Meinolf, Della Pepa, Roberta, Vinh, Donald, Noël, Nicolas, Deau Fischer, Bénédicte, Drenou, Bernard, Mitra, Maria Enza, Meletiadis, Joseph, Bilgin, Yavuz M., Jindra, Pavel, Espigado, Ildefonso, Drgoňa, Ľuboš, Serris, Alexandra, Di Blasi, Roberta, Ali, Natasha, EPICOVIDEHA working group, [missing], Pagano, Livio, Salmanton-Garcia, Jon, Marchesi, Francesco, Busca, Alessandro, Corradini, Paolo, Hoenigl, Martin, Klimko, Nikolai, Koehler, Philipp, Pagliuca, Antonio, Passamonti, Francesco, Verga, Luisa, Visek, Benjamin, Ilhan, Osman, Nadali, Gianpaolo, Weinbergerova, Barbora, Cordoba-Mascunano, Raul, Marchetti, Monia, Collins, Graham P., Farina, Francesca, Cattaneo, Chiara, Cabirta, Alba, Gomes-Silva, Maria, Itri, Federico, van Doesum, Jaap, Ledoux, Marie-Pierre, Cernan, Martin, Jaksic, Ozren, Duarte, Rafael F., Magliano, Gabriele, Omrani, Ali S., Fracchiolla, Nicola S., Kulasekararaj, Austin, Valkovic, Toni, Poulsen, Christian Bjorn, Machado, Marina, Glenthoj, Andreas, Stoma, Igor, Racil, Zdenek, Piukovics, Klara, Navratil, Milan, Emarah, Ziad, Sili, Uluhan, Maertens, Johan, Blennow, Ola, Bergantim, Rui, Garcia-Vidal, Carolina, Prezioso, Lucia, Guidetti, Anna, del Principe, Maria Ilaria, Popova, Marina, de Jonge, Nick, Ormazabal-Velez, Irati, Fernandez, Noemi, Falces-Romero, Iker, Cuccaro, Annarosa, Meers, Stef, Buquicchio, Caterina, Antic, Darko, Al-Khabori, Murtadha, Garcia-Sanz, Ramon, Biernat, Monika M., Tisi, Maria Chiara, Sal, Ertan, Rahimli, Laman, Colovic, Natasa, Schonlein, Martin, Calbacho, Maria, Tascini, Carlo, Miranda-Castillo, Carolina, Khanna, Nina, Mendez, Gustavo-Adolfo, Petzer, Verena, Novak, Jan, Besson, Caroline, Dulery, Remy, Lamure, Sylvain, Nucci, Marcio, Zambrotta, Giovanni, Zak, Pavel, Seval, Guldane Cengiz, Bonuomo, Valentina, Mayer, Jiri, Lopez-Garcia, Alberto, Sacchi, Maria Vittoria, Booth, Stephen, Ciceri, Fabio, Oberti, Margherita, Salvini, Marco, Izuzquiza, Macarena, Nunes-Rodrigues, Raquel, Ammatuna, Emanuele, Obr, Ales, Herbrecht, Raoul, Nunez-Martin-Buitrago, Lucia, Mancini, Valentina, Shwaylia, Hawraa, Sciume, Mariarita, Essame, Jenna, Nygaard, Marietta, Batinic, Josip, Gonzaga, Yung, Regalado-Artamendi, Isabel, Karlsson, Linda Katharina, Shapetska, Maryia, Hanakova, Michaela, El-Ashwah, Shaimaa, Borbenyi, Zita, Colak, Gokce Melis, Nordlander, Anna, Dragonetti, Giulia, Maraglino, Alessio Maria Edoardo, Rinaldi, Amelia, De Ramon-Sanchez, Cristina, Cornely, Oliver A., Pagano, L., Salmanton-Garcia, J., Marchesi, F., Busca, A., Corradini, P., Hoenigl, M., Klimko, N., Koehler, P., Pagliuca, A., Passamonti, F., Verga, L., Visek, B., Ilhan, O., Nadali, G., Weinbergerova, B., Cordoba-Mascunano, R., Marchetti, M., Collins, G. P., Farina, F., Cattaneo, C., Cabirta, A., Gomes-Silva, M., Itri, F., van Doesum, J., Ledoux, M. -P., Cernan, M., Jaksic, O., Duarte, R. F., Magliano, G., Omrani, A. S., Fracchiolla, N. S., Kulasekararaj, A., Valkovic, T., Poulsen, C. B., Machado, M., Glenthoj, A., Stoma, I., Racil, Z., Piukovics, K., Navratil, M., Emarah, Z., Sili, U., Maertens, J., Blennow, O., Bergantim, R., Garcia-Vidal, C., Prezioso, L., Guidetti, A., del Principe, M. I., Popova, M., de Jonge, N., Ormazabal-Velez, I., Fernandez, N., Falces-Romero, I., Cuccaro, A., Meers, S., Buquicchio, C., Antic, D., Al-Khabori, M., Garcia-Sanz, R., Biernat, M. M., Tisi, M. C., Sal, E., Rahimli, L., Colovic, N., Schonlein, M., Calbacho, M., Tascini, C., Miranda-Castillo, C., Khanna, N., Mendez, G. -A., Petzer, V., Novak, J., Besson, C., Dulery, R., Lamure, S., Nucci, M., Zambrotta, G., Zak, P., Seval, G. C., Bonuomo, V., Mayer, J., Lopez-Garcia, A., Sacchi, M. V., Booth, S., Ciceri, F., Oberti, M., Salvini, M., Izuzquiza, M., Nunes-Rodrigues, R., Ammatuna, E., Obr, A., Herbrecht, R., Nunez-Martin-Buitrago, L., Mancini, V., Shwaylia, H., Sciume, M., Essame, J., Nygaard, M., Batinic, J., Gonzaga, Y., Regalado-Artamendi, I., Karlsson, L. K., Shapetska, M., Hanakova, M., El-Ashwah, S., Borbenyi, Z., Colak, G. M., Nordlander, A., Dragonetti, G., Maraglino, A. M. E., Rinaldi, A., De Ramon-Sanchez, C., Cornely, O. A., Finizio, O., Fazzi, R., Sapienza, G., Chauchet, A., Van Praet, J., Prattes, J., Dargenio, M., Rossi, C., Shirinova, A., Malak, S., Tafuri, A., Ommen, H. -B., Bologna, S., Khedr, R. A., Choquet, S., Joly, B., Ceesay, M. M., Philippe, L., Kho, C. S., Desole, M., Tsirigotis, P., Otasevic, V., Borducchi, D. M. M., Antoniadou, A., Gaziev, J., Almaslamani, M. A., Garcia-Pouton, N., Paterno, G., Torres-Lopez, A., Tarantini, G., Mellinghoff, S., Grafe, S., Borschel, N., Passweg, J., Merelli, M., Barac, A., Wolf, D., Shaikh, M. U., Thieblemont, C., Bernard, S., Funke, V. A. M., Daguindau, E., Khostelidi, S., Nucci, F. M., Martin-Gonzalez, J. -A., Landau, M., Soussain, C., Laureana, C., Lacombe, K., Kohn, M., Aliyeva, G., Piedimonte, M., Fouquet, G., Rego, M., Hoell-Neugebauer, B., Cartron, G., Pinto, F., Alburquerque, A. M., Passos, J., Yilmaz, A. F., Redondo-Izal, A. -M., Altuntas, F., Heath, C., Kolditz, M., Schalk, E., Guolo, F., Karthaus, M., Della Pepa, R., Vinh, D., Noel, N., Deau Fischer, B., Drenou, B., Mitra, M. E., Meletiadis, J., Bilgin, Y. M., Jindra, P., Espigado, I., Drgona, L., Serris, A., Di Blasi, R., Ali, N., Stem Cell Aging Leukemia and Lymphoma (SALL), Salvy-Córdoba, Nathalie, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Università cattolica del Sacro Cuore = Catholic University of the Sacred Heart [Roma] (Unicatt), University Hospital of Cologne [Cologne], Cologne Excellence Cluster on Cellular Stress Responses in Aging-Associated Diseases (CECAD), University of Cologne, IFO - Istituto Nazionale Tumori Regina Elena [Roma] (IRE), Città della Salute e della Scienza University-Hospital, IRCCS Istituto Nazionale dei Tumori [Milano], University of California [San Diego] (UC San Diego), University of California (UC), Medical University of Graz, Odessa National I.I.Mechnikov University, Faculty of Medicine [Cologne], University Hospital of Cologne [Cologne]-University of Cologne, King's College Hospital (KCH), Universitá degli Studi dell’Insubria = University of Insubria [Varese] (Uninsubria), Dipartimento di Medicina e Chirurgia = School of Medicine and Surgery [Monza], Università degli Studi di Milano-Bicocca = University of Milano-Bicocca (UNIMIB), Faculty of Medicine in Hradec Kralove [Republique Tchèque], Charles University [Prague] (CU), Ankara University School of Medicine [Turkey], Azienda Ospedaliera Universitaria Integrata of Verona, Masaryk University [Brno] (MUNI), Fundación Jiménez Díaz, Fundacion Jimenez Diaz [Madrid] (FJD), Ospedale SS Antonio e Biagio e Cesare Arrigo, Churchill Hospital Oxford Centre for Haematology, IRCCS San Raffaele Scientific Institute [Milan, Italie], ASST Spedali Civili of Brescia, Vall d'Hebron Institute of Oncology [Barcelone] (VHIO), Vall d'Hebron University Hospital [Barcelona], Universitat Autònoma de Barcelona (UAB), Instituto Português de Oncologia de Lisboa Francisco Gentil, Ospedale San Luigi Gonzaga, University Medical Center Groningen [Groningen] (UMCG), Institut de Cancérologie de Strasbourg Europe (ICANS), Palacky University Olomouc, Zagreb School of Medicine [Zagreb, Croatia] (Dubrava University Hospital), University of Zagreb, Hospital Universitario Puerta de Hierro-Majadahonda [Madrid, Spain], ASST Great Metropolitan Niguarda / ASST Grande Ospedale Metropolitano Niguarda [Milan, Italia], Hamad Medical Corporation [Doha, Qatar], Fondazione IRCCS Ca' Granda - Ospedale Maggiore Policlinico, University of Rijeka, Croatian Cooperative Group for Hematological Diseases (CROHEM), Zealand University Hospital [Roskilde, Denmark], Hospital General Universitario 'Gregorio Marañón' [Madrid], Department of Clinical Microbiology [Rigshospitalet], Rigshospitalet [Copenhagen], Copenhagen University Hospital-Copenhagen University Hospital, Homieĺ State Medical University (GSMU), Institute of Hematology and Blood Transfusion [Prague, Czech Republic], University of Szeged [Szeged], University Hospital Ostrava, Mansoura University [Egypt], Marmara University [Kadıköy - İstanbul], Catholic University of Leuven - Katholieke Universiteit Leuven (KU Leuven), Karolinska University Hospital [Stockholm], Instituto de Investigação e Inovação em Saúde (I3S), Universidade do Porto = University of Porto, Instituto de Patologia e Imunologia Molecular da Universidade do Porto (IPATIMUP), Hospital de São João [Porto], Faculdade de Medicina da Universidade do Porto (FMUP), Clinic Barcelona Hospital Universitari, Department of Public Health and Cell Biology, University of Rome Tor Vergata, Via Montpellier 1, 00133 Rome, Italy, Pavlov First Saint Petersburg State Medical University [St. Petersburg], Vrije Universiteit Medical Centre (VUMC), Vrije Universiteit Amsterdam [Amsterdam] (VU), Complejo Hospitalario de Navarra, Hospital Universitario Marqués de Valdecilla [Santander], La Paz University Hospital, Azienda Usl Toscana centro [Firenze], AZ Klina, Clinical Center of Serbia (KCS), University of Belgrade [Belgrade], Sultan Qaboos University Hospital, Partenaires INRAE, Hospital Universitario de Salamanca, Servicio de Haematologia, Centro de Investigación del Cáncer-IBMCC (USAL-CSIC), University of Wrocław [Poland] (UWr), San Bortolo Hospital, Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), Hospital Universitario 12 de Octubre [Madrid], Azienda Sanitaria Universitaria Friuli Centrale (ASU FC), Universidad Rey Juan Carlos [Madrid] (URJC), University of Basel (Unibas), Innsbruck Medical University = Medizinische Universität Innsbruck (IMU), University Hospital Kralovské Vinohrady, Centre Hospitalier de Versailles André Mignot (CHV), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Institut de Génétique Moléculaire de Montpellier (IGMM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), Département Hématologie biologique [CHRU Montpellier], Pôle Biologie-Pathologie [CHRU Montpellier], Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Universidade Federal do Estado do Rio de Janeiro (UNIRIO), San Gerardo Hospital of Monza, Oxford NIHR Biomedical Research Centre, IRCCS Ospedale San Raffaele [Milan, Italy], Assi Sette Llaghi Varese, Instituto Português de Oncologia do Porto / Portuguese Oncology Institute of Porto (IPO Porto), University Hospital Olomouc [Czech Republic], ASST Grande Ospedale Metropolitano Niguarda, University Hospital Centre Zagreb, Instituto Nacional do Câncer, Copenhagen University Hospital, Republican Scientific and Practical Center (RSPC) for organ and Tissue Transplantation, Minsk, Republican Scientific and Practical Center (RSPC) for Organ and Transplantation, German Centre for Infection Research (DZIF), Gilead Sciences, Pagano, Livio [0000-0001-8287-928X], Salmanton-García, Jon [0000-0002-6766-8297], Marchesi, Francesco [0000-0001-6353-2272], Busca, Alessandro [0000-0001-5361-5613], Corradini, Paolo [0000-0002-9186-1353], Hoenigl, Martin [0000-0002-1653-2824], Klimko, Nikolay [0000-0001-6095-7531], Koehler, Philipp [0000-0002-7386-7495], Pagliuca, Antonio [0000-0003-2519-0333], Passamonti, Francesco [0000-0001-8068-5289], Verga, Luisa [0000-0003-1142-8435], Víšek, Benjamin [0000-0001-8268-452X], Ilhan, Osman [0000-0003-1665-372X], Weinbergerová, Barbora [0000-0001-6460-2471], Córdoba, Raúl [0000-0002-7654-8836], Marchetti, Monia [0000-0001-7615-0572], Farina, Francesca [0000-0002-5124-6970], Cattaneo, Chiara [0000-0003-0031-3237], Cabirta, Alba [0000-0001-7198-8894], Gomes-Silva, Maria [0000-0002-6993-2450], Itri, Federico [0000-0002-3532-5281], Doesum, Jaap van [0000-0003-0214-3219], Ledoux, Marie-Pierre [0000-0002-3261-3616], Čerňan, Martin [0000-0003-2345-1229], Jakšić, Ozren [0000-0003-4026-285X], Magliano, Gabriel [0000-0002-9129-1530], Omrani, Ali S. [0000-0001-5309-6358], Fracchiolla, Nicola S. [0000-0002-8982-8079], Kulasekararaj, Austin G. [0000-0003-3180-3570], Valković, Toni [0000-0001-6083-8815], Poulsen, Christian Bjørn [0000-0001-9785-1378], Machado, Marina [0000-0002-8370-2248], Glenthøj, Andrea [0000-0003-2082-0738], Stoma, Igor [0000-0003-0483-7329], Ráčil, Zdeněk [0000-0003-3511-4596], Piukovics, Klára [0000-0003-4480-3131], Emarah, Ziad [0000-0003-0622-2598], Sili, Uluhan [0000-0002-9939-9298], Maertens, Johan [0000-0003-4257-5980], Bergantim, Rui [0000-0002-7811-9509], García-Vidal, Carolina [0000-0002-8915-0683], Prezioso, Lucia [0000-0003-1660-4960], Principe, Maria Ilaria del [0000-0002-3958-0669], Popova, Marina [0000-0001-8536-5495], Jonge, Nick de [0000-0002-9901-0887], Ormazabal-Vélez, Irati [0000-0003-1141-5546], Falces-Romero, Iker [0000-0001-5888-7706], Cuccaro, Annarosa [0000-0002-0237-1839], Meers, Stef [0000-0003-1754-2175], Buquicchio, Caterina [0000-0002-3683-5953], Antić, Darko [0000-0002-2608-1342], Al-Khabori, Murtadha [0000-0002-2937-8838], García-Sanz, Ramón [0000-0003-4120-2787], Biernat, Monika [0000-0003-3161-3398], Tisi, Maria Chiara [0000-0001-8231-6700], Sal, Ertan [0000-0003-2761-2675], Rahimli, Laman [0000-0003-2266-445X], Schönlein, Martin [0000-0002-1010-0975], Calbacho, María [0000-0001-8106-4863], Tascini, Carlo [0000-0001-9625-6024], Miranda-Castillo, Carolina [0000-0001-8763-9576], Khanna, Nina [0000-0002-2642-419X], Méndez, Gustavo-Adolfo [0000-0003-0514-7004], Petzer, Verena [0000-0002-9205-1440], Besson, Caroline [0000-0003-4364-7173], Duléry, Rémy [0000-0002-5024-1713], Lamure, Sylvain [0000-0001-5980-305X], Nucci, Marcio [0000-0003-4867-0014], Zambrotta, Giovanni [0000-0002-8612-2994], Žák, Pavel [0000-0003-4465-5343], Cengiz Seval, Guldane [0000-0001-9433-2054], Bonuomo, Valentina [0000-0001-6491-8337], Mayer, Jiří [0000-0003-0567-9887], López-García, Alberto [0000-0002-5354-5261], Sacchi, Maria Vittoria [0000-0001-8133-3357], Booth, Stephen [0000-0003-2687-0234], Ciceri, Fabio [0000-0003-0873-0123], Nunes-Rodrigues, Raquel [0000-0002-8347-4281], Ammatuna, Emanuele [0000-0001-8247-4901], Obr, Aleš [0000-0002-6758-3074], Herbrecht, Raoul [0000-0002-9381-4876], Shwaylia, Hawraa [0000-0002-4098-6092], Sciumè, Mariarita [0000-0001-7958-4966], Essame, Jenna [0000-0003-0926-5577], Batinić, Josip [0000-0001-5595-9911], Gonzaga, Yung [0000-0003-1416-2118], Regalado-Artamendi, Isabel [0000-0002-9673-9015], Karlsson, Linda Katharina [0000-0003-3317-7550], Shapetska, Maryia [0000-0002-1223-9161], El-Ashwah, Shaimaa [0000-0003-2210-1534], Çolak, Gökçe Melis [0000-0002-7662-7454], Dragonetti, Giulia [0000-0003-1775-6333], Rinaldi, Amelia [0000-0002-8211-5076], Ramón, Cristina de [0000-0002-8167-6410], Cornely, Oliver A. [0000-0001-9599-3137], Institut Català de la Salut, [Pagano L] Hematology, Fondazione Policlinico Universitario Agostino Gemelli - IRCCS – Università Cattolica del Sacro Cuore, Rome, Italy. Università Cattolica del Sacro Cuore, Rome, Italy. [Salmanton-García J] Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Excellence Center for Medical Mycology (ECMM), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. Cologne Excellence Cluster On Cellular Stress Responses in Aging Associated Diseases (CECAD), University of Cologne, Faculty of Medicine and University Hospital Cologne, Cologne, Germany. [Marchesi F] Hematology and Stem Cell Transplant Unit, IRCCS Regina Elena National Cancer Institute, Rome, Italy. [Busca A] Stem Cell Transplant Center, AOU Citta’ Della Salute E Della Scienza, Turin, Italy. [Corradini P] University of Milan and Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy. [Hoenigl M] Division of Infectious Diseases and Global Public Health, Department of Medicine, University of California San Diego, San Diego, CA, USA. Clinical and Translational Fungal Working Group, University of California San Diego, La Jolla, CA, USA. Section of Infectious Diseases and Tropical Medicine, Department of Internal Medicine, Medical University of Graz, Graz, Austria. [Cabirta A, Izuzquiza M] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain. Departament de Medicina, Universitat Autònoma de Barcelona, Bellaterra, Spain, Vall d'Hebron Barcelona Hospital Campus, Hematology, Salmanton-García, Jon, Klimko, Nikolay, Víšek, Benjamin, Weinbergerová, Barbora, Córdoba, Raúl, Doesum, Jaap van, Čerňan, Martin, Jakšić, Ozren, Magliano, Gabriel, Kulasekararaj, Austin G., Valković, Toni, Poulsen, Christian Bjørn, Glenthøj, Andrea, Ráčil, Zdeněk, Piukovics, Klára, García-Vidal, Carolina, Principe, Maria Ilaria del, Jonge, Nick de, Ormazabal-Vélez, Irati, Antić, Darko, García-Sanz, Ramón, Biernat, Monika, Schönlein, Martin, Calbacho, María, Méndez, Gustavo-Adolfo, Duléry, Rémy, Žák, Pavel, Cengiz Seval, Guldane, Mayer, Jiří, López-García, Alberto, Obr, Aleš, Sciumè, Mariarita, Batinić, Josip, Çolak, Gökçe Melis, Ramón, Cristina de, and Universidad de Sevilla. Departamento de Medicina

Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Male, Cancer Research, MESH: Registries, Epidemiology, MESH: Hospitalization, Hematological malignancies, Otros calificadores::Otros calificadores::/complicaciones [Otros calificadores], MESH: Aged, 80 and over, MESH: Risk Factors, [SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Risk Factors, Malalties - Factors de risc, Risk of mortality, Medicine and Health Sciences, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], 80 and over, Medicine, MESH: COVID-19, Registries, Sang - Malalties - Complicacions, RC254-282, Cause of death, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Interna medicina, MESH: Aged, Aged, 80 and over, Hematology, MESH: Middle Aged, Mortality rate, Neoplasms. Tumors. Oncology. Including cancer and carcinogens, Myeloid leukemia, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Middle Aged, CANCER, Europe, Hospitalization, Intensive Care Units, Oncology, MESH: Young Adult, Hematologic Neoplasms, [SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseases, Female, BIOMEDICINA I ZDRAVSTVO. Kliničke medicinske znanosti. Infektologija, Life Sciences & Biomedicine, Adult, medicine.medical_specialty, [SDV.CAN]Life Sciences [q-bio]/Cancer, COVID-19, EHA, Pandemic, Aged, Humans, SARS-CoV-2, Young Adult, técnicas de investigación::métodos epidemiológicos::estadística como asunto::probabilidad::riesgo::factores de riesgo [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], [SDV.CAN] Life Sciences [q-bio]/Cancer, Intensive care, Internal medicine, Diseases of the blood and blood-forming organs, MESH: SARS-CoV-2, neoplasias::neoplasias por localización::neoplasias hematológicas [ENFERMEDADES], Molecular Biology, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Internal Medicine, pandemic, hematological malignancies, epidemiology, MESH: Humans, Science & Technology, business.industry, Myelodysplastic syndromes, Research, MESH: Adult, Neoplasms::Neoplasms by Site::Hematologic Neoplasms [DISEASES], medicine.disease, BIOMEDICINE AND HEALTHCARE. Clinical Medical Sciences. Infectology, Settore MED/15, MESH: Male, Settore MED/15 - MALATTIE DEL SANGUE, [SDV.SPEE] Life Sciences [q-bio]/Santé publique et épidémiologie, COVID-19 (Malaltia) - Diagnòstic, MESH: Intensive Care Units, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie, Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Probability::Risk::Risk Factors [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], MESH: Europe, RC633-647.5, business, MESH: Female, Other subheadings::Other subheadings::/complications [Other subheadings], MESH: Hematologic Neoplasms
Abstract

Background Patients with hematological malignancies (HM) are at high risk of mortality from SARS-CoV-2 disease 2019 (COVID-19). A better understanding of risk factors for adverse outcomes may improve clinical management in these patients. We therefore studied baseline characteristics of HM patients developing COVID-19 and analyzed predictors of mortality. Methods The survey was supported by the Scientific Working Group Infection in Hematology of the European Hematology Association (EHA). Eligible for the analysis were adult patients with HM and laboratory-confirmed COVID-19 observed between March and December 2020. Results The study sample includes 3801 cases, represented by lymphoproliferative (mainly non-Hodgkin lymphoma n = 1084, myeloma n = 684 and chronic lymphoid leukemia n = 474) and myeloproliferative malignancies (mainly acute myeloid leukemia n = 497 and myelodysplastic syndromes n = 279). Severe/critical COVID-19 was observed in 63.8% of patients (n = 2425). Overall, 2778 (73.1%) of the patients were hospitalized, 689 (18.1%) of whom were admitted to intensive care units (ICUs). Overall, 1185 patients (31.2%) died. The primary cause of death was COVID-19 in 688 patients (58.1%), HM in 173 patients (14.6%), and a combination of both COVID-19 and progressing HM in 155 patients (13.1%). Highest mortality was observed in acute myeloid leukemia (199/497, 40%) and myelodysplastic syndromes (118/279, 42.3%). The mortality rate significantly decreased between the first COVID-19 wave (March–May 2020) and the second wave (October–December 2020) (581/1427, 40.7% vs. 439/1773, 24.8%, p value, EPICOVIDEHA has received funds from Optics COMMITTM (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223).

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results